










Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Krogager, M. L. (2020). Importance of potassium in patients with antihypertensive medication – a Danish register
based approach. Aalborg Universitetsforlag. Aalborg Universitet. Det Sundhedsvidenskabelige Fakultet. Ph.D.-
Serien
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: August 24, 2021
IMPORTANCE OF POTASSIUM IN PATIENTS 
WITH ANTIHYPERTENSIVE MEDICATION 





























































































Dissertation submitted: September 2020
PhD supervisor:  Professor Christian Torp-Pedersen, MD, DMSc
Department of Cardiology and Clinical Research
Nordsjællands Hospital, Hillerød, Denmark.
Co-PhD supervisor: Professor Peter Søgaard, MD, DMSc
Department of Cardiology,
Aalborg University Hospital, Denmark.
Assistant PhD supervisor: Kristian Kragholm, MD, PhD
Department of Cardiology,
Aalborg University Hospital, Denmark.
PhD committee: Clinical Professor Torben Bjerregaard Larsen (chair)
Department of Clinical Medicine
Aalborg University
Professor Patrick Rossignol
Centre d’Investigation Clinique Plurithématique Pierre 
Drouin-INSERM CHU de Nancy,
Université de Lorraine, FCRIN INI-CRCT, Nancy
Clinical Associate Professor Kristina Procida
Department of Clinical Medicine
Zealand University Hospital
PhD Series: Faculty of Medicine, Aalborg University










© Copyright: Maria Lukács Krogager
Printed in Denmark by Rosendahls, 2021
3 
Papers 
This PhD thesis is based on the following studies: 
I. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis
of nationwide registry data
Maria Lukács Krogager, Christian Torp-Pedersen, Rikke Nørmark Mortensen, Lars Køber, Gunnar 
Gislason, Peter Søgaard, Kristian Aasbjerg.  
European	Heart	Journal,	7	January	2017	
https://doi.org/10.1093/eurheartj/ehw129	
II. Impact of plasma potassium normalization on short-term mortality in patients with
hypertension and hypokalemia or low normal potassium
Maria Lukács Krogager, Peter Søgaard, Christian Torp-Pedersen, Henrik Bøggild, Christina Ji-
Young Lee, Anders Bonde, Jesper Q. Thomassen, Gunnar Gislason, Manan Parek, Kristian Kragholm
BMC Cardiovascular disorders, 24 August 2020 
https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-020-01654-3  
III. Impact of plasma potassium normalization on short-term mortality in patients with
hypertension and hyperkalemia
Maria Lukács Krogager, Peter Søgaard, Christian Torp-Pedersen, Henrik Bøggild, Gunnar 
Gislason, Kristian Kragholm 
IV. Risk of developing hypokalemia in patients with hypertension treated with combination
antihypertensive therapy
Maria Lukács Krogager, Rikke Nørmark Mortensen, Peter Enemark Lund, Henrik Bøggild, 
Steen Møller Hansen, Kristian Kragholm, Kristian Aasbjerg, Peter Søgaard, Christian Torp-
Pedersen 





Potassium has a pivotal role in cardiovascular disease and maintenance of potassium homeostasis is 
essential to prevent adverse events. Individuals with hypertension are one large subgroup of patients 
with heart disease that are usually prescribed drugs with effect on blood potassium concentrations. 
Often, targeted blood pressure is achieved with combination therapy only, which can lead to 
potassium disarrays. The normal potassium interval (serum potassium: 3.5-5.0 mmol/L, plasma 
potassium 3.5-4.6 mmol/L) is defined based on apparently healthy individuals, and levels outside this 
range are associated with increased morbidity and mortality.  
This thesis examines optimal potassium concentrations and impact of potassium normalization after 
the first episode with hypo- or hyperkalemia on short-term mortality in patients with hypertension 
treated with at least two classes of antihypertensive drugs. We also investigated short-term 
hypokalemia risk in relation to different combinations of antihypertensive therapies. 
Study I. From 1995-2012, 44,799 patients with hypertension were treated with minimum two 
antihypertensive drug classes and had at least one potassium measurement within 90-days from 
treatment initiation. The relationship between potassium and mortality was U-shaped. We observed 
that patients with potassium concentrations outside the interval 4.1-4.7 mmol/L including low and 
high normal potassium range had increased short-term mortality risk (90-days follow-up) compared 
to the reference (K: 4.1-4.4 mmol/L). 
Study II. A total of 8,976 patients with hypertension and potassium concentrations ≤ 3.7 mmol/L at 
the first measurement within 100 days from hypertension diagnosis were identified. We retained the 
results of a second potassium draw within 6-100 days after the episode with hypokalemia. Of the 
patients with potassium levels between 3.5-3.7 mmol/L at the first draw, 13% had measurements 
below 3.5 mmol/L and 5.7% had concentrations above 4.6 mmol/L at the second draw. Persistent 
hypokalemia (<3.5 mmol/L) was frequent (28.5%) and associated with increased short-term all-cause 
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and cardiovascular death.  Increased all-cause and cardiovascular mortality risk was also observed 
when low potassium concentrations were overcorrected to levels above 4.6 mmol/L.   
Study III. We included 7,620 patients with hypertension and potassium concentrations ≥4.7 mmol/L 
(hyperkalemia) at the first measurement within 100-days from diagnosis. A subsequent measurement 
within 6-100 days following the first draw was required. The results showed that potassium 
concentrations outside the interval 4.1-5.5 mmol/L after an episode with hyperkalemia were 
associated with increased all-cause and cardiovascular mortality risk. 
Study IV. By matching 463 patients with hypokalemia to 926 patients with normal potassium 
concentrations, we observed that combinations of thiazides with calcium channel blockers, beta-
blockers or renin-angiotensin system inhibitors were associated with increased odds of developing 
hypokalemia within 90-days of treatment initiation, regardless of potassium supplementation. 
In conclusion, our studies suggested that a more strict normal potassium interval (4.1-4.7 mmol/L) 
was beneficial in patients with hypertension. Persistent hypokalemia was associated with poor 
outcomes. Patients with initial plasma potassium concentrations between 3.5-3.7 mmol/L were at 
high risk of mortality, partly because of further decrease in potassium and partly due to 
overcorrection. Increase in potassium concentrations >4.6 mmol/L after an episode with potassium 
≤3.7 mmol/L was associated with increased risk of all-cause and cardiovascular mortality. Decrease 
in plasma potassium to levels <4.1 mmol/L and potassium concentrations >5.5 mmol/L after an 
episode with hyperkalemia were associated with increased risk of all-cause and cardiovascular 
mortality. Combination of any antihypertensive drugs with thiazide diuretics was associated with high 





Kalium har en central rolle i udviklingen af hjertekarsygdomme. For at forhindre komplikationer hos 
patienter der er kendt med hjertesygdomme er opretholdelse af kalium homeostasen essentiel. 
Patienter behandlet for hypertension er en stor subgruppe af patienter med hjertesygdom, der ofte er 
ordineret medicin med virkning på kalium koncentrationen i blodet. Kombinationsterapi er tit 
nødvendig for at opnå den anbefalede blodtryk, hvilket kan føre til kaliumforstyrrelser. Det normale 
kaliuminterval (serum kalium:3.5-5.0 mmol / L, plasma kalium:3.5-4.6 mmol / L) er defineret baseret 
på tilsyneladende sunde individer, og niveauer uden for dette område er forbundet med øget 
sygelighed og dødelighed. 
Denne afhandling undersøger de optimale kaliumkoncentrationer hos patienter med hypertension 
behandlet med mindst to klasser af antihypertensiva. Derudover, kigger vi på virkningen af 
kaliumnormalisering efter den første episode med hypo- eller hyperkaliæmi på overlevelsen hos 
samme patientgruppe. Sidst, undersøgte vi sandsynligheden for hurtig indsættende hypokaliæmi i 
relation til forskellige kombinationer af antihypertensiv behandling. 
Studie I. Fra 1995 til 2012 identificerede vi  44,799 patienter med hypertension behandlet med mindst 
to klasser af antihypertensiva som havde mindst en kaliummåling inden for 90-dage efter 
behandlingsstart. Vi observerede i U-formet sammenhæng mellem kalium og 90-dages dødeligheden. 
Patienter med kaliumkoncentrationer uden for intervallet 4.1-4.7 mmol/L havde øget risiko for 90-
dages dødelighed sammenlignet med referencen (K: 4.1-4.4 mmol / L). 
Studie II. Vi identificerede 8,976 patienter med hypertension med kaliumkoncentrationer ≤3.7 
mmol/L, ved den første måling, inden for 100 dage fra behandlingsstart. Vi gemte resultaterne af en 
anden måling fortaget inden for 6-100 dage efter episoden med hypokalæmi eller borderline 
hypokaliæmi. Af patienterne med kaliumniveauer mellem 3.5-3.7 mmol/L ved den første måling 
havde 13% målinger under 3.5 mmol/L ved den anden måling og 5.7% havde koncentrationer over 
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4.6 mmol/L ved den anden måling. Vedvarende hypokaliæmi (<3.5 mmol/L) var hyppig (28.5%) og 
forbundet med øget kardiovaskulær død og død af alle årsager. Forøget dødelighed (kardiovaskulær 
og af alle årsager) blev også observeret, når lave kaliumkoncentrationer blev overkorrigeret til 
niveauer over 4.6 mmol/L. 
Studie III. Vi inkluderede 7,620 patienter med hypertension og kaliumkoncentrationer ≥4,7 mmol/L 
(hyperkaliæmi) ved den første måling inden for 100 dage efter start kombinationsbehandling. En 
efterfølgende måling inden for 6-100 dage efter den første mål var påkrævet. Resultaterne viste, at 
kalium koncentrationer udenfor intervallet 4.1-5.5 mmol/L, efter episode med hyperkaliæmi, var 
associerede med forøget risiko for kardiovaskulær død og død af alle årsager. 
Studie IV. Ved at matche 463 patienter med hypokaliæmi med 926 patienter med normale 
kaliumkoncentrationer, observerede vi, at kombinationer af thiazider med calciumkanalblokkere, 
beta-blokkere eller renin-angiotensin system inhibitorer var forbundet med høj sandsynlighed for 
hypokaliæmi inden for 90 dage efter start kombinationsbehandling, på trods af kaliumtilskud hos 
mange patienter. 
Afslutningsvis, viste vores studier, at et mere snævert normalt kaliuminterval (4.1-4.7 mmol/L) var 
forbundet med større sandsynlighed for overlevelse hos patienter med hypertension behandlet med 
mindst to klasser af antihypertensiva. Vedvarende hypokaliæmi var forbundet med dårlig korttids 
prognose. Patienter med initiel plasma kalium niveau mellem 3.5-3.7 mmol/L havde øget risiko for 
kortids dødelighed, dels pga. yderligere fald i kalium og dels pga. overkorrektion. Fald i 
kaliumkoncentrationer til niveauer <4.1 mmol/L og >5.5 mmol/L var forbundet med øget risiko for 
kardiovaskulær død og død af alle årsager. Kombination af antihypertensiva med thiazid diuretika 
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Worldwide, approximately 26% of the population is diagnosed with hypertension and the prevalence 
is anticipated to increase to 29% by 2025.1 Hypertension increases the risk of cardiovascular disease 
and is considered the most important modifiable risk factor for disability and adjusted life-years2,3.  
Hypertension is defined as systolic blood pressure (SBP) values ≥140 mmHg and/or diastolic blood 
pressure (DBP) values ≥90 mmHg.4 Hypertension can be classified according to its etiology as 
primary or as secondary to other diseases such as hyperaldosteronism, diabetic nephropathy or 
coarctation of the aorta.5  Based on office blood pressure measurements, hypertension can be 
subdivided into four categories: grade 1 hypertension (SBP 140-159 mmHg and/or DBP 90-99 
mmHg), grade 2 hypertension (SBP 160-179 mmHg and/or DBP 100-109 mmHg), grade 3 
hypertension (SBP ≥180 mmHg and/or DBP ≥110 mmHg) and isolated systolic hypertension (SBP 
≥140 mmHg and DBP <90 mmHg).4 
Management of arterial hypertension implies non-pharmacological and pharmacological strategies. 
To achieve optimal blood pressure control, most of the patients require drug therapy in addition to 
lifestyle changes. Guidelines recommend five major drug classes for treatment of hypertension: 
diuretics (especially thiazides and thiazide-like diuretics), calcium channel blockers (CCBs), beta-
blockers (BB), angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers 
(ARBs).4 Despite the effectiveness of antihypertensive medication, only approximately 30% of the 
patients with high blood pressure achieve the therapeutic goal of <140/90 mmHg with monotherapy.6 
As a result, a large proportion of the patients require combination antihypertensive therapy, which 
can lead to adverse events. One of the most common side effects of antihypertensive medication is 





Potassium is the most abundant cation in the intracellular fluid and normal cell function is highly 
dependent on maintaining a proper distribution of potassium across the cell membrane.8 Regulation 
of potassium homeostasis is a complex process with many participating actors. In the following 
paragraphs, a brief summary of the most important mechanism are listed. 
The sodium and potassium pump (Na+-K+ ATPase) controls the potassium gradient between the 
extracellular and intracellular fluid, a process also known as internal potassium balance. Insulin and 
catecholamines are among the most important factors in regulating this process.9  
The kidney is the main actor of external potassium homeostasis, eliminating approximately 90% of 
the ingested potassium.10 Unbound potassium is filtered in the glomerulus and less than 10% of the 
filtered load reaches the distal nephron. The rate of potassium excretion is highly dependent on 
potassium reabsorption and secretion.11 The highest proportion of potassium is reabsorbed in the 
proximal convoluted tubule and thick ascending Loop of Henle, while potassium secretion occurs 
mainly in the distal tubule and collecting duct. Reabsorption in the proximal tubule is primarily a 
passive process proportional to the amount of water and sodium. Potassium absorption along the thick 
ascending Loop of Henle occurs through both transcellular and paracellular pathways.9,12 Aldosterone 
has a major role in stimulating potassium secretion. First, aldosterone stimulates the activity of the 
Na+-K+ ATPase in the basolateral membrane, process that results with increased intracellular 
potassium concentration. Second, aldosterone stimulates sodium reabsorption across the luminal 
membrane with potassium secretion into the lumen in consequence. Lastly, aldosterone increases 
luminal membrane permeability to potassium.13 The rate of distal delivery of sodium and water is 
also a major determinant affecting potassium secretion. Increased sodium concentration in the distal 
nephron stimulates its reabsorption, which makes the luminal potential more negative and, hence, 
increases potassium secretion.9  
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In patients with chronic kidney disease there is an adaptive increase in potassium secretion in the 
healthy nephrons, such that potassium homeostasis is maintained until a drop in glomerular filtration 
rate below 15-20 ml/min.14 
1.3 Potassium biochemistry (blood potassium measurement) 
Blood potassium concentrations can be measured both in serum and in plasma.15 During the clotting 
process, platelets burst and release potassium, resulting in higher potassium levels in serum as 
compared to plasma.16 Studies have shown that the difference between serum and plasma potassium 
concentrations is minimal in the lower end (<0.1 mmol/L) and substantial in the higher end (>0.5 
mmol/L).17  
The normal potassium reference interval is based on measurements from healthy individuals and 
depends on the population and the methods used to assess blood potassium concentrations. Table 1.1 
gives an overview on reference intervals for potassium in both serum and plasma for different 
populations. The normal range for serum potassium is 3.5-5.0 mmol/L, whereas levels between 3.5-
4.6 mmol/L are considered normal for plasma potassium.17–19 
Table 1.1 Reference intervals for potassium in serum and plasma in different populations  
Population US18 German17 Nordic19 
Plasma reference interval 3.4-4.8 mmol/L 3.5-4.6 mmol/L 3.5-4.4 mmol/L 
Serum reference interval 3.5-5.1 mmol/L 3.7-5.1 mmol/L 3.6-4.6 mmol/L 
 





Figure 1.1 Definitions of normokalemia, hypokalemia and hyperkalemia (potassium concentrations assessed in plasma).  
 
As intracellular potassium concentration is approximately 40 times greater than the extracellular 
concentration, even small sampling errors that would result in release of a small amount of 
intracellular potassium will falsely increase potassium levels. Pseudohyperkalemia is defined as a 
difference of more than 0.4 mmol/L between serum and plasma potassium concentrations, given that 
the samples remain at room temperature and are tested within an hour from collection.20 There are 
different causes of pseudohyperkalemia: mechanical causes (tourniquet, fist clenching, traumatic 
venipuncture, inappropriate needle diameter), temperature (above room temperature or between 2oC 
and 8oC), chemical factors (ethanol), time, thrombocytosis, alkalosis and contaminants.15  
Pseudohypokalemia is not just as common as pseudohyperkalemia, but can be encountered in blood 
draws with very high white cell count kept at room temperature for a long time and blood samples 





Potassium has a pivotal role in the development and exacerbation of cardiovascular diseases.22 
Potassium has vasodilatory effect, thus, a blood pressure lowering property.23 Clinical studies 
demonstrated that high-sodium and low-potassium diet causes sodium retention and raises blood 
pressure. On average, SBP increased by 6 mmHg and DBP by 4 mmHg in normotensive participants, 
and SBP increased by 7 mmHg and DBP by 6 mmHg in hypertensive participants.24,25  
Most cases of hypokalemia and hyperkalemia occur in the setting of specific disease states such as 
cardiovascular and renal disease. In patients with ongoing cardiovascular disease, cardiac medication 
is the main cause of potassium disarrays.26,27 Thiazide and loop diuretics decrease blood potassium 
concentrations, while potassium sparing diuretics, beta-blockers, angiotensin converting enzyme 
inhibitors and angiotensin receptor blockers commonly cause hyperkalemia.26,28  
A great focus is set on preventing dyskalemias because of their arrhythmogenic effect, especially in 
patients with heart disease who already have a high proarrhythmic substrate. The electrophysiology 
of hypokalemia and hyperkalemia is rather complex, and the electrophysiological effects that 
typically induce cardiac arrhythmias are not solely based on potassium disarrays, but also on balances 
of sodium and calcium.29 In the two following subparagraphs, electrophysiological consequences, 
symptoms and electrocardiographic manifestations and treatment of hypokalemia and hyperkalemia 
are presented. However, it is important to note that electrocardiographic changes are not always 
present in patients with dyskalemias and that electrocardiographic changes depend on the severity of 
potassium imbalances.  
1.4.1 Hypokalemia 
The electrophysiological effects of hypokalemia on cardiac conduction system include: resting 
membrane hyperpolarization, Na+-K+ ATPase inhibition, prolongation of action potential duration, 
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reduced repolarization reserve, automaticity, early afterdepolarization-mediated arrhythmias and 
delayed afterdepolarization-mediated arrhythmias.29 
Typically, the earliest electrocardiographic manifestation of hypokalemia is decreased T-wave 
amplitude or inversion (mild hypokalemia), followed by ST-segment depression, T-wave inversion, 
PR-interval prolongation and U-wave (moderate hypokalemia).30–34 Sinus bradycardia, atrial and 
ventricular tachycardia or ventricular fibrillation and Torsades de Pointes are commonly seen 
arrhythmias in patients with severe hypokalemia.31,35,36 Yet, some patients, even with severe 
hypokalemia, do not have electrocardiographic changes.32  
Most of the patients with mild hypokalemia do not experience any symptoms. The clinical 
manifestations of hypokalemia include fatigue, muscle weakness, cardiac arrhythmias or cramping 
and gastrointestinal hypomotility.30 
Management of hypokalemia includes three strategies: (1) identification of the underlying cause, (2) 
decrease potassium losses (commonly through renal or gastrointestinal system) and (3) replenishing 
of potassium stores (e.g. according to the severity p.o. or i.v. of potassium chloride, potassium 
phosphate, potassium bicarbonate). 
1.4.2 Hyperkalemia 
 The cardiac electrophysiological effects of systemic hyperkalemia are: action potential duration 
shortening, increased repolarization reserve and decreased conduction velocity.29 The earliest 
electrocardiographic sign of hyperkalemia is tall T-waves. In patients with hyperkalemia, the 
electrocardiogram can also show P-wave flattening, PR-interval prolongation, widening of the QRS 
complex and sine waves. Arrhythmias associated with hyperkalemia include sinus bradycardia, sinus 
arrest, ventricular tachycardia, ventricular fibrillation and asystole. Some of the symptoms related to 
hyperkalemia are tiredness, numbness or tingling, nausea, chest pain or palpitations.30 
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Acute, life-threatening hyperkalemia, should be treated immediately to prevent adverse outcomes and 
treatment strategies can divided into three main categories: (1) Shift of potassium from the 
extracellular into the intracellular space (β2-adrenergic agonists, insulin ± glucose, sodium 
bicarbonate in case of metabolic acidosis), (2) Heart membrane stabilization (calcium chloride or 
gluconate, hypertonic saline (3-5%)), (3) Increase potassium elimination (loop diuretics, 
hemodialysis, cation-exchange resins (sodium polystyrene sulfonate), sodium bicarbonate or 





The general aim of this thesis is to contribute to the current knowledge on goals for potassium levels 
in patients with hypertension using data from the Danish national registers. 
The specific aims of the four studies were to investigate: 
I. Short-term mortality risk associated with different potassium concentrations in patients 
treated with combination antihypertensive therapy. 
II. The impact of plasma potassium normalization on short-term mortality in patients with 
hypertension and hypokalemia or low normal potassium levels 
III. The impact of plasma potassium normalization on short-term mortality in patients with 
hypertension and hyperkalemia or high normal potassium levels 
IV. The risk of hypokalemia shortly after combination antihypertensive therapy initiation in 






All four studies in this thesis are register based cohort studies, where following nationwide registers 
were used: The Civil Registration System,38 The Danish Register of Causes of Death,39 The Danish 
National Patient Register,40,41 The Danish Prescription Register42 and The Electronic Registers of 
Laboratory Data.  
In Denmark, all citizens are given at birth or migration a personal, unique and permanent civil 
registration number, which enables cross-linkage between the administrative registers and ensures a 
high degree of follow-up.  
Information from The Civil Registration System was used in all four studies and covers data on date 
of birth, sex and vital status since 1968.38 
The Danish Register of Causes of Death supplements with information on both underlying and 
contributing causes of death, coded with an International Classification of Diseases (ICD) code. 
Before 2007, non-physicians coded the causes of death supervised by the National Board of Health. 
However, after 2007, death certificates are filled and submitted electronically by a physician without 
central validation.39 
The Danish National Patient Register contains information on all hospital admissions since April 
1977. Hospitalizations are coded with one primary and one or more secondary diagnoses using ICD-
8 codes until 1994, and ICD-10 thereafter. The register also covers data on all outpatient visits, 
emergency room and psychiatric ward contacts since 1995. Since 2003, it has been mandatory for 
private hospitals to register all contacts, yet the registration is incomplete.40,41 The Danish National 
Patient Register holds data on surgeries and clinical procedures since 1996, coded according to The 
Nordic Medical Statistics Committees Classification of Surgical Procedures.  
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The Danish Prescription Registry, also known as The Register of Medicinal Product Statistics, 
contains information about all dispensed prescriptions from outpatient pharmacies since 1994. Data 
completeness is though available from 1995. Redeemed drugs are registered according to the 
Anatomical Therapeutic Chemical Classification system (ATC).43 
The electronic registers of laboratory data do not contain nationwide data and registration is available 
since 1995. Currently, the database contains information on blood test results from The Region of 
Northern Jutland, Region of Southern Denmark, Region Zealand and Capital Region of Denmark.  
3.2 Study I 
3.2.1 Study population 
Hypertension was defined as redemption of at least two antihypertensive drug classes in two 
concomitant quarters. Patients entered the study in the second quarter. This time was referred to as 
hypertension date. ATC codes of the drugs used to identify patients with hypertension were included 
in Appendix 1.  
We used this definition of hypertension for different reasons. First, most of the patients with 
hypertension do not require hospitalization or ambulatory contact, and the Danish National Patient 
Register only registers patients with hypertension based on hospital or outpatient contacts. Had we 
identified patients with hypertension based on ICD code only, we would have excluded a considerable 
sample of patients with high blood pressure who are highly representative for the aim of this work. 
Second, many antihypertensive agents can be used for management of other cardiovascular diseases 
such as heart failure, myocardial infarction or atrial fibrillation. By using the dual- or polytherapy 
approach, we tried to ensure that high blood pressure was at least one of the causes for dispensing 
antihypertensive drugs. A similar definition was used by Olesen et al.44 where the authors defined 
hypertension as combination treatment with at least two antihypertensive drugs. The authors also 
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reported a positive predictive value of hypertension for treatment with two classes of antihypertensive 
agents of 80.0% and a specificity of 94.7%.44  
With “combination therapy/treatment” we refer to prescription of antihypertensive drugs either as 
single pill combination or as a combination of two or more individual blood pressure drugs. 
After identifying individuals with hypertension based on combination therapy, we retained the first 
available potassium measurement within 90 days from the hypertension date. Patients younger than 
30 years were excluded. The population was censored after 90-day follow-up or December 31, 2012, 
whichever came first.  
3.2.2 Comorbidities and drugs 
Besides age and sex we identified following relevant comorbidities dated before hypertension date: 
chronic obstructive pulmonary disease, stroke, atrial fibrillation, acute myocardial infarction, heart 
failure, renal insufficiency and diabetes. Most of the patients with diabetes are treated in the primary 
sector and are not registered with an ICD code for diabetes in the Danish National Patient Register. 
Therefore, we defined diabetes as dispensed prescriptions of glucose lowering drugs (see Appendix 
2 for ICD and ATC codes used). Serum sodium measurements available the same day as serum 
potassium were retained. Renal insufficiency was defined based on creatinine measurement obtained 
the same day as serum potassium or within a week from serum potassium measurement. Patients were 
regarded as having renal insufficiency if serum creatinine level was: 
>105 µmol/L for men ≤70 years 
 >125 µmol/L for men >70 years 
 >90 µmol/L for women ≤70 years 
>105 µmol/L for women >70 years19,45 
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Patients with past history of acute kidney disease, chronic kidney disease (including proteinuria) and 
primary hyperaldosteronism were excluded from the study. Besides antihypertensive medication we 
also identified potassium supplements due to their influence on potassium homeostasis. 
3.2.3 Exposure variable 
In this study both serum and plasma potassium measurements were used to perform the analyses, as 
we could not differentiate between the two methods of measuring blood potassium concentrations. 
We referred to all measurements as serum potassium. Potassium levels outside 1.5 times the 
interquartile range above the upper quartile (>5.8 mmol/L) and bellow the lower quartile (<2.9 
mmol/L) were regarded as outliers and were excluded. 
Seven potassium intervals were constructed: <3.5, 3.5-3.7, 3.8-4.0, 4.1-4.4, 4.5-4.7, 4.8-5.0 and >5.0 
mmol/L. Hypokalemia was defined as potassium <3.5 mmol/L and hyperkalemia as concentrations 
>5.0 mmol/L. Serum potassium interval 4.1-4.4 mmol/L was used as reference for statistical analyses. 
It was chosen based on restricted cubic splines results and based on lowest number of events observed. 
3.2.4 Outcome definition 
The outcome of the study was 90-day all-cause mortality.  
3.2.5 Statistical analysis 
Baseline characteristics were presented as frequencies and percentages or means with standard 
deviation. To estimate the differences of continuous variables, we used the Kruskal-Wallis test and 
Persons’ Chi-squared test was used for categorical variables. The probability of 90-day survival for 
the seven potassium intervals was illustrated using Kaplan-Meier survival curve. Cox proportional 
hazard model was used to investigate the association between the different potassium intervals and 
short-term mortality in patients with hypertension. The assumptions of linearity, interaction with 
relevant variables and proportionality of the hazards were assessed. We used “age” as a categorical 
variable in the adjusted model as no linearity with short-term mortality was observed. We predefined 
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four age intervals: 30-50 years, 51-70 years (reference), 71-80 years, and >80 years. The following 
variables were tested for interaction with potassium on mortality: age, sex, diabetes and renal 
insufficiency. The multivariable model was adjusted for age, gender, chronic obstructive pulmonary 
disease, stroke, atrial fibrillation, acute myocardial infarction, heart failure, renal insufficiency and 
diabetes. As for antihypertensive medication, we included in the adjusted model the five most 
prescribed antihypertensive combination therapies observed in our population: ACEIs/ARBs+BB, 
ACEIs/ARBs+CCB, ACEIs/ARBs+Thiazides+Potassium supplement (reference in the statistical 
analyses), BB+Thiazides+Potassium supplement. Combinations outside top five were named “Other 
combinations of antihypertensive medication”. Besides potassium supplements as single pill therapy 
with thiazides, we also accounted for potassium supplements as an individual pill in the multivariable 
analysis. 
We also assessed the association between potassium as a continuous variable and short-term mortality 
using restricted cubic splines with knots at the 10th, 25th, 50th, 75th and 90th percentiles of potassium. 
The 90-day mortality risk was presented as hazard ratios (HR) with 95% confidence intervals 
(95%CI). P-values below 0.05 were considered statistically significant. Analyses were performed 
with SAS (version 9.4, SAS institute, Cary, NC, USA) and R statistical software (version 3.0.1, R 
development core team).46 
3.3 Study II 
3.3.1 Study population 
We identified patients with hypertension treated with at least two classes of antihypertensive drugs. 
Rationale for using this definition of hypertension is presented in section 3.2.1. Thereafter, we 
retained the first plasma potassium measurement within 100 days from hypertension date and patients 
with concentrations ≤3.7 mmol/L were included in the study. This potassium measurement was 
referred to as K1. We identified a second potassium measurement (K2) in the interval 6-100 days from 
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K1, and the first draw within this timeframe was retained. Blood tests performed within 1-5 days from 
K1 were not included in the analyses as potassium imbalances are usually corrected within a few days, 
regardless of the strategies applied. Patients younger than 18 years were excluded from the study. 
Appendix 3 (flowchart) illustrates the patient selection for Study II.  
3.3.2 Comorbidities and drugs 
Comorbidities associated with dyskalemias were dated up to five years before the index date (K2 date) 
were identified: heart failure, ischemic heart disease, stroke, chronic obstructive pulmonary disease, 
chronic liver disease, diabetes mellitus, inflammatory bowel disease and malignancy. Furthermore, 
patients with a past history of primary adrenal insufficiency, primary hyperaldosteronism, and 
diabetes insipidus were excluded (see Appendix 2 for ICD codes). Based on creatinine measurements, 
we calculated the estimated glomerular filtration rate (eGFR) using Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation47. Significant renal insufficiency was defined as an 
eGFR < 30 mL/min/1.73 m2. Patients with unavailable creatinine measurements the same day as or 
within a week from the index date were excluded.  
The following hypo- and hyperkalemia associated drug prescriptions redeemed up to 90-days before 
the index date were identified: potassium supplements, non-steroidal anti-inflammatory drugs, 
corticosteroids, laxatives, xanthines and antimicrobials (Appendix 2 includes relevant ATC codes).  
3.3.3 Exposure variable 
For K2 we constructed seven plasma potassium intervals: 1.5-2.9 mmol/L, 3.0-3.4 mmol/L, 3.5-3.7 
mmol/L, 3.8-4.0 mmol/L and K: 4.1-4.6 mmol/L, 4.7-5.0 mmol/L, and 5.1-7.1 mmol/L. Plasma 
potassium interval K: 3.8-4.0 mmol/L was used as reference for statistical analyses. We chose this 
interval as the reference group because it had the largest number of patients and lowest mortality rate. 
Hypokalemia was defined as plasma potassium concentrations below 3.5 mmol/L and borderline 
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hypokalemia as potassium levels within the interval 3.5-3.7 mmol/L. Hyperkalemia was defined as 
potassium levels above 4.6 mmol/L.17  
3.3.4 Outcome definition 
The primary outcome was 60-day all-cause mortality. The secondary outcome was presumed 
cardiovascular death within 60 days of follow-up. 
3.3.5 Statistical analysis 
Continuous variables were presented as median with corresponding 25th and 75th percentiles and 
categorical variables as counts and percentages. Differences between variables were compared using 
Kruskal-Wallis and Chi2 tests, as appropriate.  
Survival probability for the seven plasma potassium intervals was illustrated using Kaplan-Meier 
curves. To investigate the relationship between plasma potassium as a continuous variable and 60-
day mortality, we constructed a restricted cubic splines curve illustrating absolute mortality risk in an 
age, sex, comorbidity and drug standardized population.  
To assess the risk of 60-day all-cause and presumed cardiovascular mortality in relation to the seven 
potassium intervals we used Cox proportional hazard model. The multivariable model was adjusted 
for: age, sex, serum sodium, renal insufficiency, malignancy, heart failure, chronic liver disease, 
chronic obstructive pulmonary disease, diabetes mellitus, atrial flutter/fibrillation, stroke and 
ischemic heart disease, antihypertensive therapy, corticosteroids, antimicrobials, non-steroidal anti-
inflammatory drugs, potassium supplement, xanthines and laxatives.  
Based on the Cox regression principle, we also modelled an average effect to estimate the 60-day 
absolute risk of all-cause mortality. 
The proportional hazard assumption was tested by plotting Schoenfeld residuals and was not violated. 
Interactions on mortality were tested by comparing the likelihood ratio of the Cox regression model 
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with and without the interaction term. The following variables were tested for interaction with plasma 
potassium on mortality: age, sex, diabetes mellitus and renal insufficiency.  A two-sided p-value 
< 0.01 was considered statistically significant for interactions. We found no statistically significant 
interactions. For other analyses, the level of statistical significance was set at <0.05. Linearity of age 
on mortality was also assessed through a likelihood ratio test comparing a linear description with a 
categorical one. Age was found to violate linearity and was included as a categorical variable with 
five levels, using cut-off values from every 20th percentiles (55, 64, 72, 79 and 101 years). Hazard 
ratios (HR) were estimated with 95% confidence intervals (95% CI). All data management and 
analyses were performed using SAS, version 9.4 and R, version 3.5.0.46 
3.4 Study III 
3.4.1 Study population 
We identified patients with hypertension treated with at least two classes of antihypertensive drugs. 
Rationale for using this definition of hypertension is presented in section 3.2.1. First plasma 
potassium measurement within 100 days from hypertension date was retained and patients with 
concentrations ≥4.7 mmol/L (hyperkalemia) were included in the study. This potassium measurement 
was referred to as K1. We identified a second potassium measurement (K2) in the interval 6-100 days 
from K1 and the first draw within this timeframe was retained. Like in study II, we did not analyze 
on potassium drawn within 1-5 days from K1, as in most circumstances dyskalemias are balanced 
within a few days. Patients below 18 years were excluded from the study (Appendix 4 for population 
flowchart).  
3.4.2 Comorbidities and drugs 
We identified comorbidities and medication that either clinically or theoretically can be regarded as 
confounders in examining the relation between plasma potassium and mortality. The following 
comorbidities were identified: heart failure, chronic obstructive pulmonary disease, ischemic heart 
disease, chronic liver disease, stroke, diabetes, inflammatory bowel disease and malignancy. 
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Moreover, we excluded patients with prior history of primary adrenal insufficiency, primary 
hyperaldosteronism, or diabetes insipidus. The ICD codes used to identify these comorbidities can be 
seen in Appendix 2. Like in Study II, renal dysfunction was defined as an eGFR < 30 mL/min/1.73 
m2 and eGFR was calculated using CKD-EPI formula.47 We retained creatinine measurements 
available the same day as K2 or within a week from K2 in case of missing values the same day. Patients 
were excluded if no creatinine concentrations were available in this time limit. Additionally, patients 
with missing sodium measurements the same day as K2 were also excluded.  
3.4.3 Exposure variable  
As Study I demonstrated a non-linear relationship between potassium and short-term mortality, K2 
was divided into eight intervals: 2.2-2.9 mmol/L, 3.0-3.4 mmol/L, 3.5-3.7 mmol/L, 3.8-4.0 mmol/L, 
4.1-4.6 mmol/L, 4.7-5.0 mmol/L, 5.1-5.5 mmol/L and 5.6-7.8 mmol/L. Plasma potassium interval 
4.1-4.6 mmol/L was used as reference for statistical analyses. Hypokalemia was defined as plasma 
potassium concentrations below 3.5 mmol/L and hyperkalemia and potassium levels above 4.6 
mmol/L.48 
3.4.4 Outcome definition 
The primary outcome of the study was 90-day all-cause mortality. The secondary outcome was 
cardiovascular death within 90 days of follow-up. 
3.4.5 Statistical analysis 
Categorical variables were presented as counts and percentages, and continuous variables as median 
and 25th and 75th percentiles. Differences between variables were compared using Kruskal-Wallis and 
Chi2 tests, as appropriate.  
Survival probability in the eight predefined plasma potassium strata was illustrated using Kaplan-
Meier curves. To investigate the relationship between plasma potassium as a continuous variable and 
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90-day mortality, we constructed a restricted cubic splines curve with knots at the 25th, 50th and 75th 
percentiles of plasma potassium.  
Cox proportional regression model was used to investigate the association between the eight 
potassium groups and mortality. Proportionality of the hazards assumption was tested using log-rank 
test and Schoenfeld residuals. Age, gender, diabetes and renal dysfunction were tested for interaction 
with potassium on mortality. A likelihood ratio test comparing the model with and without the 
interaction term was performed. A p-value under 0.01 was considered as a statistically significant 
interaction. We observed no interaction between potassium and age, gender, diabetes or renal 
dysfunction on mortality. The same approach was used to assess whether age had a linear relationship 
on mortality. As the linearity assumption was not fulfilled for age as a continuous variable, age was 
included in the regression models as a categorical variable with five levels, using cut-off values from 
20th percentiles: 18-58, 59-67, 68-73, 74-81, 82-102. The multivariable model was adjusted for: age, 
sex, plasma sodium, renal insufficiency, malignancy, heart failure, chronic liver disease, chronic 
obstructive pulmonary disease, diabetes mellitus, stroke, atrial flutter/fibrillation, ischemic heart 
disease, inflammatory bowel disease, antihypertensive therapy, corticosteroids, antimicrobials, non-
steroidal anti-inflammatory drugs, xanthines, laxatives, digoxin and potassium supplements. Hazard 
rate ratios (HR) were estimated with 95% confidence intervals (95% CI).  
Nine sensitivity analyses were conducted to test the robustness of the main results: (1) subgroup of 
patients with normal kidney function; (2) patients without past history of any malignancy; (3) patients 
without past history of heart failure or loop diuretic prescriptions; (4) patients without past history of 
ischemic heart disease; (5) patients with available ICD-10 hypertension diagnosis; (6) analyses 
investigating risk of cardiovascular death in relation to the eight potassium intervals; (7) analyses 
using last instead of first available potassium concentrations within 6-100 days from first 
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measurement; (8) multivariable model adjusted for the first potassium measurement as well, and (9) 
multivariable model adjusted for time between first and second potassium measurement as well. 
In the survival analyses p-values <0.05 were considered statistically significant. All data management 
and analyses were performed using SAS, version 9.4 and R, version 3.5.0.46 
3.5 Study IV 
3.5.1 Study population 
We identified patients with hypertension treated with at least two classes of antihypertensive drugs. 
Rationale for using this definition of hypertension is presented in section 3.2.1. The first potassium 
measurement within 90 days from hypertension date was kept. The following exclusion criteria were 
applied: age <18 years, no available potassium measurements up to 30 days before index date, 
hypokalemia or hyperkalemia up to 30 days before index date, hyperkalemia at the first potassium 
measurement within 90 days from hypertension date.  The population flowchart with inclusion and 
exclusion criteria is illustrated in Appendix 5. 
We used a case-control design and incidence density matching to match two patients without 
hypokalemia (K+, ≥3.5 mmol/L) to a patients with hypokalemia (K+, <3.5 mmol/L)  on age, sex, renal 
function and time between hypertension date and date of potassium draw.  
3.5.2 Comorbidities and drugs 
To characterize the population, we identified following discharge diagnoses or outpatient contacts 
with ICD-10 diagnoses present before hypertension date: ischemic heart disease, heart failure, acute 
myocardial infarction, atrial fibrillation, atrial flutter, second- or third-degree atrioventricular block, 
ventricular tachycardia or fibrillation, stroke, chronic obstructive pulmonary disease, chronic liver 
disease, inflammatory bowel disease, diabetes mellitus, hypothyroidism, cancer, and stroke. 
Exclusion criteria were past history of diabetes insipidus, syndrome of inappropriate antidiuretic, 
hormone secretion, primary hyperaldosteronism, or Addison disease. Estimated glomerular filtration 
31 
 
rate (eGFR) was calculated based on creatinine measurements using the formula developed by the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).47 Renal insufficiency was defined 
as an eGFR<30 mL/min per 1.73 m2. Creatinine measurement was obtained the same day as 
potassium or within 7 days before potassium measurement. Patients with missing creatinine values 
within this time frame were excluded. 
From the Danish National Prescription Registry, drugs associated with dyskalemias were identified: 
potassium supplements, antimicrobials, β2-agonists, mineralo- and glucocorticoids, laxatives, 
xanthines, and macrolides. We identified both potassium supplements as single pill therapy with a 
diuretic or as an individual pill. Only potassium supplementation, antimicrobials, and β2-agonists 
were present in the nested case-control population. Both ICD and ATC codes of the above mentioned 
conditions and drugs are illustrated in Appendix 2. 
3.5.3 Exposure variable 
The exposure variable defining the combinations of antihypertensive drugs in the population was 
divided into ten groups according to the frequency: 
1. BB+CCB 
2. BB+RASi 
3. BB+RASi+mineral receptor antagonist 
4. BB+RASi+thiazides 
5. BB+thiazides 




10. Other combinations 
32 
 
When mentioning CCBs, we refer to dihydropyridine derivatives, such as amlodipine. We used 
CCB+RASi as reference in the multivariable analysis as this combination was one of the most 
commonly prescribed in our population and theoretically not associated with hypokalemia. 
3.5.4 Outcome definition 
Outcome was onset of hypokalemia within 90 days of follow-up. 
3.5.5 Statistical analysis 
Conditional logistic regression analysis was used to estimate the odds of hypokalemia within 90 days 
from hypertension date in relation to different combinations of blood pressure drugs. The 
multivariable model was adjusted for: sodium, malignancy, inflammatory bowel disease, diabetes 
mellitus and chronic liver disease.  
Some antihypertensive drugs can be used in the management of ischemic heart disease or heart 
failure. Therefore, we performed a sensitivity analysis where we also matched the controls on past 
history with ischemic heart disease/acute myocardial infarction and heart failure. Apart from this, we 
also assessed the prevalence of different diseases in patients treated with combination 
antihypertensive therapy who did not have a potassium measurement available within 90 days from 
the hypertension date. 
Categorical variables were reported as counts and percentages and continuous variables as medians 
with 25th to 75th percentiles. Differences between variables were compared using Chi2 and Kruskal-
Wallis tests, as appropriate. Odds ratios (OR) with p-values below 0.05 were considered statistically 
significant. 
Data management and analyses were performed using SAS, version 9.4 (SAS Institute, Inc, Cary, 
NC) and R, version 3.5.1 (R Core Team [2018]). R: A language and environment for statistical 






In the period 1995-2012, Study I included 44,799 patients with hypertension, treated with at least two 
antihypertensive drug classes, who had a potassium measurement available within 90 days from the 
hypertension date. The cohort had an average age of 67.1 (±12.6) years and males accounted for 
52.8% of the population. Both mean and median serum potassium was 4.2 mmol/L. Of the total 
population, 3.8% had hypokalemia and 2.3% hyperkalemia. Women were more prone to 
hypokalemia, while men were more susceptible to hyperkalemia. Between 10-20% of the population 
had prevalent cardiovascular disease, and a similar prevalence of diabetes was found. As for 
antihypertensive therapy, about a quarter of the population was treated with the combination of 
ACEIs/ARBs+Thiazides with or without potassium supplementation (Table 4.1.1.1). The great 
majority of the population had their first potassium draw in the first 45 days (65.1%). As for mortality, 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Of the patients 866 (1.9%) had the event. Mortality within 90-days in the seven strata was: 4.5, 2.7, 
1.8, 1.5, 1.7, 2.7, and 3.6%, respectively (Table 4.1.1.1). Kaplan-Meier survival curves are illustrated 
in Figure 4.1.2.1.  
Figure 4.1.2.1 Kaplan-Meier curves displaying the estimated 90-day survival probability for seven different potassium 
intervals (n=44,799). 
 
Univariable analysis (Figure 4.1.2.2) showed that hypokalemia and hyperkalemia were associated 
with increased 90-day mortality risk (HR 3.11, 95% CI 2.41-4.00 and HR 2.47, 95% CI 1.75-3.84, 
respectively). In addition, low normal (3.5-3.7 mmol/L, HR 1.83, 95% CI 1.47-2.29) and high normal 
potassium (4.8-5.0 mmol/L, HR 1.83, 95% CI 1.41-2.36) concentrations were also associated with 
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increased risk of death within 90-days. The results of the multivariable analysis showed similar results 
(Figure 4.1.2.2). 
Figure 4.1.2.2 All-cause mortality in patients with hypertension according to seven potassium intervals (90-days follow-
up, n=44,799). Reference interval represented by K: 4.1-4.4 mmol/L. Multivariable analysis adjusted for: age, gender, 
atrial fibrillation, acute myocardial infarction, heart failure, stroke, chronic obstructive pulmonary disease, diabetes, 
potassium supplements and antihypertensive drugs. 
 
Analysis with potassium as a continuous variable showed a U-shaped relationship with short-term 













Figure 4.1.2.3 Restricted cubic splines showing the adjusted hazard ratios for all-cause mortality as a function of 
potassium concentration. Knots at the 10th, 25th, 50th, 75th, and 90th percentiles of potassium. Model adjusted for age, 
sex, chronic obstructive pulmonary disease, stroke, acute myocardial infarction, atrial fibrillation, heart failure, diabetes 
mellitus, potassium supplement, antihypertensive medication (n=44,799). 	
 
4.1.3 Sensitivity analyses 
To reduce possible uncertainty related to the main results, we conducted three sensitivity analyses 
and the results are illustrated in Table 4.1.2.1.  
First, we performed an analysis on patients treated with combination antihypertensive therapy who 
also had a registered hypertension ICD diagnosis code in the hospital sector (n=26,126). The results 
were similar to the ones obtained in the main analysis, though with slightly lower HRs.  
Second, patients who redeemed loop diuretics were excluded as they are primarily used in heart 
failure management and not hypertension, which was our target population. Overall, we observed the 
same significant associations and trends as in our initial findings. 
Third, we excluded patients with past history of myocardial infarction and/or heart failure as both 
diseases are associated with increased mortality risk and in both cases patients can be prescribed 
antihypertensive medication, without necessarily having high blood pressure. The analysis suggested 
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that potassium concentrations outside the interval 4.1-4.7 mmol/L were associated with poor 
prognosis.   
Table 4.1.2.1 Sensitivity analyses 
Potassium 
(mmol/L)  
Hypertension definition based on 
ICD codes (n = 26,126) 
Patients with loop diuretic 
prescription were excluded (n = 
35,393) 
Patients with an acute myocardial 
infarction or heart failure diagnosis 
before hypertension were excluded (n 
= 35,827) 













2.9–3.4  1.91  1.63  2.24  <0.01  3.49  2.43  5.00  <0.01  2.99  2.21  4.06  <0.01  
3.5–3.7  1.49  1.28  1.74  <0.01  2.03  1.48  2.79  <0.01  1.89  1.44  2.48  <0.01  
3.8–4.0  1.14  0.98  1.32  0.10  1.24  0.94  1.64  0.12  1.31  1.04  1.66  0.02  
4.1–4.4  1  Reference  1  Reference  1  Reference  
4.5–4.7  1.18  0.98  1.43  0.07  0.95  0.69  1.30  0.74  1.18  0.91  1.53  0.22  
4.8–5.0  1.38  1.07  1.78  0.01  1.50  1.01  2.22  0.04  1.85  1.34  2.55  <0.01  




We identified 8,976 patients treated with multiple antihypertensive agents, who had potassium 
concentrations ≤3.7 mmol/L within the first 100 days from hypertension date. Approximately 50% 
of the population was hospitalized at K1 and 80% at K2. Median time from K1 to K2 was 22 days (25th 
and 75th percentiles: [6,100]). Of the patients with potassium levels within 3.5-3.7 mmol/L K1, 13% 
developed hypokalemia and 5.7% hyperkalemia at K2. As for patients with hypokalemia at K1, we 
observed that 28.5% remained hypokalemic at the second blood draw and 4.8% developed 
hyperkalemia. Related to K2, thiazides were more common in patients with potassium levels ≤3.7 
mmol/L, whereas loop diuretics were more common among patients with hyperkalemia. Of the total 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Totally, 7% (n=627) of the population died within 60-days from K2. Mortality in the seven strata was: 
14.4%, 7.0%, 6.3%, 5.2%, 6.7%, 13.6% and 21.6%, respectively (Table 4.2.1.1, Figure 4.2.2.1).  




A significant association with all-cause mortality was observed in patients with hypokalemia (1.5-2.9 
mmol/L HR 2.39, 95% CI 1.66-3.43 and 3.0-3.4 mmol/L HR 1.36, 95% CI 1.04-1.78) and 
hyperkalemia (4.7-5.0 mmol/L HR 2.36, 95% CI 1.68-3.30 and 5.1-5.7 mmol/L HR 2.62, 95% CI 
1.73-3.98) (Figure 4.2.2.2). The univariable analysis showed similar results (Figure 4.2.2.2). There 
was no interaction between K1 and K2 on 60-day mortality.  
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Figure 4.2.2.2 All-cause and cardiovascular mortality after hypokalemia or borderline hypokalemia according to 
subsequent potassium measurements in patients treated with combination antihypertensive therapy (60-days follow-up, 
n=8,976). Potassium interval K: 3.8-4.0 mmol/L represented the reference range. Adjusted for age, gender, serum sodium, 
renal insufficiency, malignancy, heart failure, chronic liver disease, chronic obstructive pulmonary disease, diabetes 
mellitus, atrial flutter/fibrillation, stroke and ischemic heart disease, antihypertensive therapy, corticosteroids, 
antimicrobials, non-steroidal anti-inflammatory drugs, potassium supplement, xanthines, laxatives. 
 
As for cardiovascular mortality, we observed that about 53% of all deaths were recorded as having a 
cardiovascular cause. Significant associations with cardiovascular death were observed in patients 
with potassium concentrations <3.0 mmol/L and above 4.6 mmol/L after an episode with plasma 
potassium ≤3.7 mmol/L (Figure 4.2.2.2). The standardized 60-day absolute risk of all-cause mortality 
in relation to potassium was lowest in patients with potassium levels between 3.8–4.0 mmol/L (AR 




Table 4.2.2.1 60-day standardized absolute risk for all-cause death after hypokalemia or borderline hypokalemia 
according to subsequent potassium measurements in patients treated with combination antihypertensive therapy 
(n = 8976). Potassium interval K: 3.8–4.0 mmol/L represented the reference range. Adjusted for age, gender, serum 
sodium, renal insufficiency, malignancy, heart failure, chronic liver disease, chronic obstructive pulmonary disease, 
diabetes mellitus, atrial flutter/fibrillation, stroke and ischemic heart disease, antihypertensive therapy, corticosteroids, 
antimicrobials, non-steroidal anti-inflammatory drugs, potassium supplement, xanthines, laxatives 
 
Absolute risk %, 
(95% CI)  
60-d Risk difference %, 
(95%CI)  
p-value Average risk ratio %, 
(95%CI)  
p-value  
P(K) 1.5–2.9 mmol/L  11.7% (8.3–15.0)  6.3 (2.9–9.7)  < 0.001  2.17 (1.46–2.88)  0.001  
P(K) 3.0–3.4 mmol/L  7.1% (5.8–8.5)  1.7 (0.1–3.4)  0.03  1.32 (0.99–1.66)  0.06  
P(K) 3.5–3.7 mmol/L  6.4% (5.3–7.5)  1.0 (− 0.3–2.4)  0.14  1.19 (0.91–1.47)  0.17  
P(K) 3.8–4.0 mmol/L  5.4% (4.5–6.3)  REF.    REF.    
P(K) 4.1–4.6 mmol/L  6.3% (5.4–7.2)  0.9 (−0.3–2.2)  0.13  1.18 (0.92–1.44)  0.17  
P(K) 4.7–5.0 mmol/L  11.6% (8.7–14.6)  6.2 (3.2–9.3)  < 0.001  2.17 (1.51–2.82)  < 0.001  
P(K) 5.1–7.1 mmol/L  12.6% (8.2–16.9)  7.2 (2.8–11.6)  0.001  2.34 (1.45–3.22)  0.003  
 
4.2.3 Subgroup and sensitivity analyses 
We performed eleven additional analyses to test the accuracy and robustness of the main results and 
the findings are enclosed in Appendix 7. Most important results are highlighted.  
Patients with borderline hypokalemia who developed hypokalemia or hyperkalemia had in increased 
60-day mortality compared to those corrected to a level within 3.8-4.0 mmol/L. 
Overall, subgroup analyses on patients without significant renal insufficiency, or without past history 
of ischemic heart disease, any malignancy or heart failure or loop diuretic prescription, showed 






Totally, 7,620 patients fulfilled the inclusion criteria and demographic characteristics according to 
the eight potassium groups are shown in Tabel 4.3.1.1. Of the total population with hyperkalemia at 
K1 about 39 % had dyskalemia at K2. We observed that 36.1% of the patients with hyperkalemia at 
K1 had elevated potassium concentrations at K2. Of the total patients, 2.9% were overbalanced to 
hypokalemia. Among patients with potassium between 4.7 and 5.5 mmol/L at K1, 3.4 % had higher 
(>5.5 mmol/L) levels at K2. The great majority of the patients had their K1 and K2 measured during 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Totally, 622 (8.2%) patients died within 90-days follow-up. Mortality reported according to the eight 
plasma potassium strata was: 37.8%, 21.2%, 14.5%, 9.6%, 6.3%, 6.2%, 10.0%, and 16.4%, 
respectively (Table 4.3.1.1). Kaplan-Meier survival curves are illustrated in Figure 4.3.2.1. Patients 
who died were older, with higher kidney insufficiency burden at K2, higher hospitalization rate at K2, 
and more likely with a previous history of malignancy, stroke, chronic obstructive pulmonary disease, 
atrial fibrillation and chronic liver disease within the past five years (Appendix 8). 
Figure 4.3.2.1 – Kaplan Meier survival curves across the eight plasma potassium intervals. The p-values indicate the 
difference among plasma potassium groups compared to the reference group based on an unadjusted Cox regression 
model. 
 
The results of the univariable and multivariable Cox proportional regression, with plasma potassium 
4.1-4.6 mmol/L as the reference group, are shown in Figure 4.3.2.2. The multivariable analysis 
showed that patients with hypokalemia following an episode with hyperkalemia have an increased 
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90-day mortality risk (2.2-2.9 mmol/L: HR 4.69, 95% CI 2.70-8.17; 3.0-3.4 mmol/L: HR 2.50, 95% 
CI 1.77-3.54). Patients with potassium concentrations between 3.5-4.0 mmol/L also had an increased 
risk of death within 90-days (3.5-3.7 mmol/L: HR 1.71, 95% CI 1.23-2.37; 3.8-4.0 mmol/L: HR 1.36, 
95% CI 1.04-1.76). As for patients with persisting hyperkalemia, we observed that potassium 
concentrations within the interval 5.6-7.8 mmol/L was associated with increased 90-day mortality 
risk (HR 2.27, 95% CI 1.60-3.20).  
Figure 4.3.2.2 All-cause mortality after hyperkalemia according to subsequent potassium measurements in patients treated 
with combination antihypertensive therapy (90-days follow-up, n=7,620). Potassium interval K: 4.1-4.6 mmol/L 
represented the reference range. 
 
4.3.3 Sensitivity analyses 
To test the robustness of our main results we performed nine sensitivity analyses (Appendix 9). 
First, we performed analysis on a subpopulation with eGFR ≥30 mL/min/1.73 m2 (n=6,505). The 
results were similar to the main analysis.  
Second, analyses using patients without past history of any malignancy (n= 6,383) showed similar 
results to the main analysis, although potassium interval 3.8-4.0 mmol/L was no longer statistically 
significant (HR 1.33, 95% CI 0.95-1.84). 
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Third, 3,149 patients had no history of heart failure and/or loop diuretic prescriptions. Analysis using 
this subgroup of patients showed that only hypokalemia was significantly associated with increased 
90-day mortality risk following an episode with hyperkalemia (2.2-2.9 mmol/L: HR 7.79, 95% CI 
2.54-23.90 and 3.0-3.4 mmol/L: HR 2.79, 95% CI 1.35-5.78).  
Fourth, analysis using patients without past history of ischemic heart disease (n= 5,121) showed 
similar results to the main analysis. Although, potassium interval 3.8-4.0 mmol/L was no longer 
statistically significant (HR 1.30, 95% CI 0.95-1.77). Conversely, potassium levels within the interval 
5.1-5.5 mmol/L were associated with increased risk of short-term mortality after an episode with 
hyperkalemia. 
Fifth, including patients with hypertension defined by relevant ICD diagnosis codes (n= 2,410), we 
observed that patients who developed hypokalemia after an episode with hyperkalemia had increased 
90-day mortality risk (2.2-2.9 mmol/L: HR 5.15, 95% CI 2.09-12.69 and 3.0-3.4 mmol/L: HR 2.84, 
95% CI 1.52-5.29). Patients with potassium concentrations above 5.0 mmol/L after an episode with 
hyperkalemia had also increased risk of death within 90-days (5.1-5.5 mmol/L: HR 2.31, 95% CI 
1.43-3.75 and 5.6-7.8 mmol/L: HR 2.54, 95% CI 1.22-5.29). 
Sixth, potassium concentrations outside the interval 4.1-5.0 mmol/L were associated with increased 
cardiovascular mortality risk (2.2-2.9 mmol/L: HR 6.86, 95% CI 3.40-13.85; 3.0-3.4 mmol/L: HR 
3.21, 95% CI 2.05-5.04; 3.5-3.7 mmol/L: HR 1.85. 95% CI 1.15-2.96; 3.8-4.0 mmol/L: HR 1.56, 
95% CI 1.09-2.25; 5.1-5.5 mmol/L: HR 1.80, 95% CI 1.26-2.57; 5.6-7.8 mmol/L: HR 2.61, 95% CI 
1.56-4.35). 
Seventh, by performing the analyses on the last available potassium draw within 6-100 days from K1, 
the results were similar to the main analysis. 
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Eighth, we performed multivariable analyses where we adjusted for potassium concentrations 
obtained at K1. The results were similar to the main analysis: potassium levels outside the interval 
4.6-5.5 mmol/L after a recent episode with hyperkalemia were associated with increased short-term 
mortality risk.  
Ninth, analyses including time between first and second potassium draw as a covariate in the 
multivariable model showed similar results to the main analysis. 
4.4 Study IV 
4.4.1 Demographics 
During 1995 to 2017, 11,896 patients fulfilled the inclusion criteria. Nearly half of the population 
was prescribed thiazide diuretics, of which 1.6 % were thiazide-like diuretics. Roughly one third of 
the population redeemed potassium supplements, mostly as single pill combined with an 
antihypertensive (86.7%). Hypokalemia represented 3.9% of the total population. Predominant 
comorbidities were ischemic heart disease, heart failure, diabetes and 2% had renal dysfunction 
(Appendix 10).  
After matching on age, sex, eGFR, renal insufficiency, and time from index date to potassium 
measurement, 463 cases and 926 controls were identified. Median time from index date to potassium 
measurement was 30 days (IQR 0, 90). Patients treated with RASi+Thiazides and CCB+Thiazides 
had the highest prevalence of hypokalemia (30.7% and 12.1%, respectively) compared to patients 










Table 4.4.1.1. Demographics of the matched population. Variables written in Italic represent the variables we matched 
on. 
  
Controls (n=926) Cases (n=463) Total (n=1389) p-value 
Gender Female 484 (52.3) 242 (52.3) 726 (52.3) 1.0 
Age median(range) 65.0(21.0, 95.0) 66.0(23.0, 95.0) 65.0(21.0, 95.0) 0.55 
Days from hypertension 
to potassium 
measurement 
median(range) 30.0(0.0, 90.0) 31.0(0.0, 90.0) 30.0(0.0, 90.0) 0.68 
Serum sodium median(range) 140.0(113.0, 146.0) 140.0(118.0, 148.0) 140.0(113.0, 148.0) 0.15 
Renal insufficiency 10 (1.1) 5 (1.1) 15 (1.1) 1.0 
eGFR median(range) 77.0(10.0, 214.0) 79.0(7.0, 222.0) 78.0(7.0, 222.0) 0.32 
Treatment 
combinations 
BB+CCB 41 (4.4) 19 (4.1) 60 (4.3) 
BB+RASi 195 (21.1) 40 (8.6) 235 (16.9) 
BB+RASi+MRA 40 (4.3) 4 (0.9) 44 (3.2) 
BB+RASi+Thiazides 33 (3.6) 23 (5.0) 56 (4.0) 
BB+Thiazides 32 (3.5) 29 (6.3) 61 (4.4) 
CCB+RASi 134 (14.5) 40 (8.6) 174 (12.5) 
CCB+RASi+Thiazides 49 (5.3) 42 (9.1) 91 (6.6) 
CCB+Thiazides 37 (4.0) 56 (12.1) 93 (6.7) 
RASi+Thiazides 264 (28.5) 142 (30.7) 406 (29.2) 
Other combinations 101 (10.9) 68 (14.7) 169 (12.2) < 0.0001 
Heart failure 153 (16.5) 30 (6.5) 183 (13.2) < 0.0001 
IHD/MI 224 (24.2) 68 (14.7) 292 (21.0) < 0.0001 
COPD 56 (6.0) 30 (6.5) 86 (6.2) 0.84 
Diabetes 
 
121 (13.1) 41 (8.9) 162 (11.7) 0.03 
Chronic liver disease 
 
24 (2.6) 9 (1.9) 33 (2.4) 0.57 
Hemodialysis ≤3 ≤3 ≤6 - 
Malignancy 115 (12.4) 73 (15.8) 188 (13.5) 0.10 
Stroke 83 (9.0) 55 (11.9) 138 (9.9) 0.11 
Atrial 
flutter/fibrillation 
120 (13.0) 41 (8.9) 161 (11.6) 0.03 
Atrioventricular block 13 (1.4) ≤3 ≤16 - 
VT/VF 36 (3.9) 13 (2.8) 49 (3.5) 0.38 
Inflammatory bowel 
disease 
16 (1.7) 11 (2.4) 27 (1.9) 0.54 
Hypothyroidism 18 (1.9) 9 (1.9) 27 (1.9) 1.0 
Potassium supplement 312 (33.7) 212 (45.8) 524 (37.7) < 0.0001 
Antimicrobials ≤3 ≤3 ≤6 - 
Beta-2 agonists ≤3 ≤3 ≤6 - 




Cumulative incidence curve drawn on the original population (n=11,898) and stratified on the ten 
combination therapies showed that CCB+Thiazides had a significantly higher incidence of 
hypokalemia (10%) compared with the other antihypertensive combination therapies (Figure 4.4.2.1).  
 
Figure 4.4.2.1 Cumulative incidence curve of hypokalemia risk stratified on the ten combination therapies 
 
The multivariable conditional logistic regression analysis with CCB+RASi as reference showed 5.82 
times increased hypokalemia odds within 90 days if administered CCB+Thiazides (95% CI 3.06-
11.08). Following blood pressure drug combinations were also associated with increased odds of 
hypokalemia: BB+Thiazides (OR 3.34, 95% CI 1.67-6.66), CCB+RASi+Thiazides (OR 3.07, 95% 
CI 1.72-5.46) and BB+RASi+Thiazides (OR 2.78, 95% CI 1.41-5.47, Figure 4.4.2.2). The univariable 






Figure 4.4.2.2. Forestplot of multivariable conditional logistic regression analysis for the development of hypokalemia. 
Population matched on age, gender, renal insufficiency and time index date initiation to serum potassium measurement. 
The model was adjusted for serum sodium, renal insufficiency, malignancy, IBD, diabetes, alcoholism and chronic liver 
disease. The combination of calcium channel blockers with renin-angiotensin system inhibitors was used as reference. 
BB- Beta Blockers, CCB- Calcium Channel Blockers, RASi- Renin-Angiotensin System Inhibitors, MRA- Mineral 
Receptor Antagonist.  
 
4.4.3 Sensitivity analyses 
We performed an additional analysis on a population matched on age, sex, eGFR, renal insufficiency, 
time from index date to potassium measurement, heart failure, and ischemic heart disease/myocardial 
infarction. The results were similar to the main analyses (Appendix 12 and 13). 
We observed that in the general population, treated with combination antihypertensive therapy who 
did not have available serum potassium measurements within 90 days from index date, the prevalence 
of most comorbidities of interest had lower proportions than in the nested case-control population 
(Appendix 14). 




To summarize, the four studies demonstrated not only the importance of maintaining potassium 
homeostasis in patients treated with at least two classes of antihypertensive drugs, but also the 
importance of aiming potassium concentrations in the middle of the currently used reference interval. 
We observed that patients with initial potassium ≤3.7 mmol/L had increased short-term mortality risk 
(all-cause and cardiovascular) if they persisted hypokalemic or if they developed hyperkalemia. As 
for patients with initial hyperkalemia, potassium concentrations above 5.5 mmol/L and below 4.1 
mmol/L were associated with increased all-cause and cardiovascular mortality. For patients on ≥2 
antihypertensive drugs, we found that use of thiazide diuretics was associated with increased odds of 
hypokalemia, regardless of concomitant administration of a blood pressure drug with opposite effect 
on blood potassium concentrations, such as RASi or potassium supplement. 
5.1 Study I 
In study I, we investigated 90-day all-cause mortality risk in relation to seven predefined potassium 
intervals. Expectedly, hypokalemia and hyperkalemia were associated with increased risk of death 
within 90 days, compared with the reference 4.1-4.4 mmol/L. However, three potassium intervals 
within normal range (3.5-3.7, 3.8-4.0 and 4.8-5.0 mmol/L) were also associated with poor short-term 
prognosis. These results were not biased by great cardiovascular disease burden as subgroup analyses 
performed on populations without loop diuretic prescriptions, past history with myocardial infarction 
and heart failure showed similar results as in the main analyses. In addition, patients with acute and 
chronic kidney disease were excluded from all analyses. This suggests that potassium levels below 
4.1 mmol/L and above 4.7 mmol/L are a risk factor of mortality in patients treated with minimum 
two classes of antihypertensive drugs. 
57 
 
Consistency in results was also observed both when defining hypertension based on combination 
antihypertensive therapy and by using ICD codes. This adds to the validity of hypertension definition 
used in this study. 
The window period of 90 days for retaining the first potassium measurement was considered 
appropriate as a review showed that, in patients with hypertension, dyskalemias as a results of adverse 
drug reaction peaked at 3 months.49 
To our knowledge, few, if any studies50 have investigated which is the optimal potassium interval in 
patients with hypertension. Most studies explored the risk of potassium disturbances related to 
different antihypertensive drugs or risk of arrhythmias in hypokalemia and hyperkalemia. Macdonald 
et al.50 recommended a potassium range between 3.5 and 5.0 mmol/L in patients with hypertension. 
This recommendation was based on studies analyzing the effect of potassium rich diet/potassium 
supplementation on lowering blood pressure or based on studies examining the risk arrhythmia in 
relation to different potassium concentrations.  
An older study by Hulting, showed that out of 1,315 patients, 3.5% had in-hospital episodes of 
ventricular fibrillation and that they typically occurred in the presence of hypokalemia.  The author 
also observed relatively high incidence of ventricular fibrillation in patients with low normal serum 
potassium concentrations: 4% in those with serum potassium between 3.5-3.8 mmol/L, 2% when 
serum potassium was between 3.9-4.2 mmol/L and 1% in patients with serum potassium between 4.3-
4.6 mmol/L.  No episodes with ventricular fibrillation was observed in patients with admission 
potassium levels above 4.6 mmol/L. The author also concluded that serum potassium concentrations 
below 3.9 mmol/L were associated with fivefold increase in the risk of ventricular tachycardia.51 
Hultings observations are quite similar with our results, though different but relatable outcomes. In 
patients with hyperkalemia arrhythmias and sudden cardiac death may occur at different thresholds. 
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In patients with chronic diseases such as heart failure, diabetes and chronic kidney disease slow rise 
in potassium over time often occurs without consequences, whereas rapid-onset hyperkalemia can be 
fatal.37   
In other populations with cardiovascular disease, we observed similar optimal potassium interval as 
in the current study. For example, in patients with acute and chronic heart failure potassium 
concentrations 3.9-4.5 mmol/L52 and  4.2-4.7 mmol/L,53 respectively, were associated with increased 
survival. Cooper et al. suggested that an optimal potassium value of 4.2 mmol/L in patients with heart 
failure.54 In patients with atrial fibrillation or flutter co-treated with diuretics and rate-or rhythm-
controlling drugs, we found that potassium levels outside the interval 3.8-4.4 mmol/L were associated 
with increased short-term mortality risk.55 As hypertension is a great risk factor for atrial fibrillation 
and flutter, we believe that this population resembles our hypertensive population. As we can see, 
there is a minimal variation in the optimal intervals recommended in different categories of heart 
disease. However, the most outstanding similarities/overlaps are that low normal (≤3.7 mmol/L) and 
high normal (≥4.8 mmol/L) potassium concentrations are associated with poor prognosis. Yet, this 
study cannot answer whether low normal and high normal potassium concentrations should be 
regarded as risk factors or risk markers. It is possible for patients with borderline potassium levels to 
develop more extreme concentrations and that low normal and high normal potassium should be 
regarded as a proxy for dyskalemias. 
5.2 Study II 
In study II, we investigated 60-day mortality among 8,976 patients with hypertension and 
hypokalemia or low normal potassium concentrations in relation to a subsequent measurement. Five 
major findings characterize the results in this study: (1) Persistent hypokalemia following plasma 
potassium concentrations ≤3.7 mmol/L was more than twice as frequent as development of 
hyperkalemia.  (2) Persistent hypokalemia associated with increased all-cause and presumed 
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cardiovascular mortality; (3) Elevation of potassium to levels >4.6 mmol/L in patients with initial 
potassium concentrations ≤3.7 mmol/L was associated with increased all-cause mortality; (4) Among 
patients with potassium levels between 3.5-3.7 mmol/L at K1, development of hypokalemia or 
hyperkalemia was associated with increased mortality risk; (5) Correcting hypokalemia was 
associated with increased survival. 
It was not a surprise that we observed significantly higher 60-day mortality risk in patients with 
potassium concentrations <3.5 or >4.6 mmol/L after an episode with potassium ≤3.7 mmol/L. In 
Study I, we noted an apparent optimal potassium range within 4.1-4.7 mmol/L in a similar 
population.56  
Our study suggested that potassium deficit is frequently underestimated than overestimated by health 
care providers as 18% of the patients still had potassium concentrations ≤3.7 mmol/L at K2 (vs. 5.4% 
>4.6 mmol/L). Hypokalemia (at K2) was present in 13% of the patients with borderline hypokalemia 
at K1. Possibly, the association of low normal potassium concentrations with mortality we noted in 
Study I, can partly be explained by further declines in potassium levels, and that low normal 
potassium concentrations might be a marker for an ongoing decrease in potassium. 
 Several studies demonstrated an association between hypokalemia and high risk of mortality among 
patients with cardiovascular disease.55,57–59 Yet, only one previous study performed on heart failure 
patients demonstrated improved 90-day survival in patients who had their hypokalemia corrected 
within 8-30 days.60 In addition, Harkness et al.63 found that patients with hypokalemia whose 
potassium level was not corrected to ≥3.5 mmol/L within 24 h were at increased odds of developing 
arrhythmias. Although, the study did not describe or account for the cause of admission, comorbidities 
or pharmacotherapy. The authors excluded patients with history of ischemic heart disease and 
arrhythmia, but included patients with heart failure who have a high arrhythmia risk. 
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A study using 5,916 participants from the general population found no significant associations 
between borderline hypokalemia (3.4-3.6 mmol/L) and risk of all-cause mortality.61 The results of 
this study and ours are very difficult to compare due to major differences in methodology, aim and 
population characteristics. First, in our population all patients are users of antihypertensive 
medication. In the study by Mattsson et al.61 49.6% of the total population had high blood pressure at 
baseline, 13.9% were prescribed heart medication and 10.9% were treated with diuretics. Second, our 
aim was to investigate the impact of correcting plasma potassium concentrations ≤3.7 mmol/L on 
short-term all-cause and cardiovascular mortality. In the study by Mattsson et al.61, mortality was 
assessed from participants’ fourth examination (between 2001-2003) until November 2014 or death, 
having a median follow-up of 11.9 years (Q1-Q3: 11.4-12.5 years). Potassium concentrations may 
not be constant over time, especially in patients with cardiovascular disease or patients treated with 
heart medication. Therefore, we believe that use of a single potassium measurement to assess 
association with long-term mortality can make interpretation of the results difficult. Shorter follow-
up time or time varying analysis where serial potassium measurements were modelled would have 
improved the methodology and results. Although, it is important to acknowledge that borderline 
hypokalemia might have different impact/effect in general population compared to our population, 
where the burden of cardiac disease is high.  
Among intensive care unit (ICU) patients, Bouadma et. al 62  investigated the effect of dyskalemia at 
admission and early dyskalemia correcting on short-term survival and cardiac events. The authors 
concluded that persisting hypokalemia or hyperkalemia within the first two days in ICU was 
associated with increased risk of death. We cannot compare the two populations, however both 
studies emphasize the importance of correcting hypokalemia to improve short-term mortality. 
As we can see, the impact of correcting hypokalemia is highly dependent on the study population and 
burden of disease, especially cardiovascular. Guidelines in the US recommend a higher threshold for 
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potassium replacement therapy (<4.0 mmol/L), especially in patients with cardiovascular disease, 
who have a high risk of developing ventricular arrhythmias.64 
5.3 Study III 
In this register-based cohort study we investigated the 90-day mortality among 7,620 patients with 
hypertension and hyperkalemia in relation to a subsequent plasma potassium measurement. 
The major findings were: (1) One third of the patients with initial hyperkalemia persisted having 
hyperkalemia at a subsequent measurement, (2) Potassium levels above 5.5 mmol/L were associated 
with increased all-cause and cardiovascular death, (3) Decrease in potassium to levels  below 4.1 
mmol/L in patients with initial hyperkalemia was associated with increased all-cause and 
cardiovascular mortality  compared with the reference (4.1-4.6 mmol/L), (4) Potassium 
concentrations between 4.1-5.5 mmol/L after an episode with hyperkalemia were associated with 
increased survival. 
Numerous studies have previously demonstrated the importance of maintaining potassium 
homeostasis in patients with cardiovascular disease. Study I, but also other studies, have also 
emphasized, that aiming potassium concentrations in the middle of the normal reference interval is 
beneficial in patients with heart disease.52,53,55,56,65,66 However, no prior studies examined the impact 
of potassium normalization during a short period of time, after an episode with hyperkalemia, in 
patients with hypertension. In this study, we observed that downregulation of potassium to levels <4.1 
mmol/L within 6-100 days after an episode with potassium >4.6 mmol/L was associated with 
increased all-cause and cardiovascular mortality. This finding confirmed the results from Study I 
where we observed an apparent optimal potassium range within 4.1-4.7 mmol/L in a similar 
population. In the same time, this study also indicated that in many cases initial hyperkalemia was 
followed by a steep downregulation of potassium, which was associated with bad prognosis.  
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A large scale study, using electronical records of 114,977 emergency department patients, 
demonstrated that in patients with hyperkalemia (≥5.5 mmol/L) at admission  (n=1033), potassium 
normalization within the first eight hours was associated with 50% mortality reduction.67 The authors 
did not present the distribution of comorbidities, however, their results are a wake-up call. In our 
study, we also observed that persisting moderate to severe hyperkalemia (plasma potassium >5.5 
mmol/L) over a period of 6-100 days was associated with higher mortality compared to 
concentrations between 4.1-4.6 mmol/L. Yet, the study populations are not comparable. 
Another study by McMahon et al.68 investigated the association between the highest potassium 
concentration on the admission day and 30-, 90- and 365-day mortality in >39,000 intensive care unit 
treated patients. The authors observed increased mortality risk in patients with potassium levels >4.5 
mmol/L. The authors also observed better prognosis in patients who had a decline in potassium 
concentration >1 mmol/L within 48 h following critical care initiation.  Our study population is not 
described by intensive care unit patients, however the results of the two studies are rather comparable. 
Our study showed a clear benefit in lowering potassium levels in patients who originally had 
concentrations above 4.6 mmol/L. However, the survival benefit was lost when potassium was 
corrected to levels below 4.1 mmol/L. 
We noted that kidney insufficiency, age, history of malignancy, stroke, chronic obstructive 
pulmonary disease, atrial fibrillation and chronic liver disease, hospitalization at the time of K2 
potassium measurement and fast down correction of high potassium levels were significant predictors 






In study IV, we estimated the odds of hypokalemia within 90 days from hypertension date in relation 
to different antihypertensive combination therapies. We observed that hypokalemia was common 
(4%) despite the short follow-up time. Thiazides were present in each of the combinations 
significantly associated with hypokalemia, regardless of supplementation with potassium in 
approximately 50% of the cases. This leads to the question whether supplementation with potassium 
was sufficient or not and whether use of thiazide-like diuretics instead of thiazide-type diuretics 
would reduce the risk of hypokalemia. In our population, only 1.6% of the patients were prescribed 
thiazide-like diuretics. A meta-analysis from 2017, concluded that thiazide-like diuretics have better 
blood pressure lowering effect without increasing the incidence of hypokalemia and hyponatremia.70  
It is also intriguing that the combination therapies significantly associated with increased 
hypokalemia risk, have opposite effects on potassium homeostasis. In a meta-analysis based on the 
results of four randomized trials, the most frequent adverse event related to CCB+diuretic was 
hypokalemia.71 Although, there is poor evidence about the risk and mechanisms of hypokalemia 
associated with the combination CCB+Thiazides. Looking at the two drugs independently, several 
studies demonstrated thiazide related hypokalemia.72–74 As for CCBs, evidence is more uncertain. On 
one hand, in vitro, in vivo and case report studies reported hyperkalemia following initiation of 
CCB.75–78 On the other hand, case studies and animal studies observed an association between 
administration of CCB and hypokalemia.79–84 It seems that CCBs augment extra-renal loss of 
potassium, while thiazides enhance renal potassium disposal.80,85–87 Despite the differences in 
mechanisms of action between the two major classes of CCBs (dihydropyridines and non-




There are no available studies comparing the risk of hypokalemia in relation to the combinations of 
Thiazides with BB or RASi. Most studies compare the risk of hypokalemia in patients treated with 
thiazides versus other classes of antihypertensives.  
Unquestionably, we should not forget that besides drugs, also advanced chronic disease states, diet 
and genetics can be responsible for potassium homeostasis disruption, especially hypokalemia. 





All four studies included in this PhD thesis are based on Danish national registers, and the limitations 
mainly relate to the observational nature. This means that our findings cannot implicate causal 
inference. Data registered in the national registers is primarily collected for administrative purposes 
and secondarily for research. Therefore, the validity of the data is highly dependent on the ICD codes 
used to define different diseases. The ICD codes allocated each patient after hospitalization or out-
patients visit are besides national surveillance also used for reimbursement, which can lead to a 
diagnostic drift towards diagnoses with the highest reimbursement.88 Moreover, clinically relevant 
data such as alcohol consumption, ejection fraction, symptoms related to dyskalemias (vomiting, 
diarrhea, arrhythmias), and treatment indication were not available, which may lead to residual 
confounding. Though, there are also many advantages and strengths linked with register based studies 
such as: low costs, large sample size, limited selection bias, and (nearly) no loss to follow-up.89  
Applicable to all four studies was the definition of hypertension based on redemption of minimum 
two antihypertensive drug classes in two concomitant quarters. Despite validation of a similar 
definition44, there still are some limitations attached to it. First, in order to capture patients who have 
not been ascertained ICD-code of hypertension, we used blood pressure lowering drugs as a proxy. 
This can lead to identification of patients with other cardiovascular diseases (heart failure, atrial 
fibrillation and ischemic heart disease) where same medication can be used to treat or ease symptoms. 
In other words, misclassification bias can be present. Second, by using this definition of hypertension, 
we miss those patients with high blood pressure treated with monotherapy only. Still, by identifying 
patients based solely on monotherapy, we would have increased the misclassification bias as no 
treatment indication was available. Third, patients with high blood pressure who did not receive 
medication or was registered an ICD code from the secondary sector could have been misclassified 
as healthy. Fourth, the results cannot be generalized to the entire population treated for high blood 
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pressure, as we did not included patients on monotherapy or patients where lifestyle changes were 
preferred in order to lower blood pressure. 
Another limitation that applies all four studies is missing information about blood draw indication. 
Some patients might have been tested due to hypokalemia or hyperkalemia symptoms, while others 
were tested during hospitalization or regular check-up at the general practitioner. In addition, we did 
not have information about the quality of the blood draws. Yet, in case of significant deviations from 
the norms, no values were reported to the registries. 
In the following paragraphs I will present the major strengths and limitations that apply each study 
individually.     
6.1 Study I 
To obtain a normal distribution of potassium measurements and account for possible bias in 
potassium measurement, we excluded outliers, which resulted with few extreme concentrations. We 
do not believe that this represents a great limitation for the study as the main aim was to investigate 
whether potassium concentrations even within the normal reference interval were associated with 
increased mortality. 
At the time this study was performed we could not differentiate between serum and plasma potassium 
measurement, which represents a limitation of the study. We referred to all measurements as serum 
potassium. The lower reference range does not really differ in the two methods of measuring 
potassium. However, the higher reference range can vary with more than 0.5 mmol/L.17 We recently 
performed a validation study, where we only used plasma potassium measurements. The results 
resembled the original study.90 In addition, the validation study also assessed the risk of 
cardiovascular mortality within 90 days from potassium measurement. We observed that potassium 





A major limitation of the two studies was the inability to investigate which initiatives physicians 
undertook to correct the initial low/high plasma potassium concentrations. The Danish National 
Prescription Registry records filled prescriptions and changes in dosage of a prescribed drug or 
treatment given during hospitalization is not registered.  
Likewise, we were unable to compare electrocardiographic findings in patients whose plasma 
potassium was normalized or remained decreased/elevated. Although, our results should be 
considered hypothesis generating associations.  
Last, in both studies we assessed the risk of presumed cardiovascular death in relation to potassium. 
Autopsies are not common in Denmark, therefore we cannot be certain that patients were attributed 
correctly cardiac vs. non-cardiac cause of death.  
6.3 Study IV 
A major strength of this study is that we ensured that all participants were normokalemic up to 30 
days before inclusion in the study. This strengthens the hypothesis that hypokalemia was induced by 
antihypertensive medication. Although, a great limitation of this study was missing information about 
the dosage of redeemed antihypertensive drugs. Due to the short follow-up time it was impossible to 
calculate the dosage. In as such, we cannot rule out the possibility that the associations observed could 
be dose dependent. Moreover, problems with compliance and overdose could not be identified, which 
can lead to non-differential misclassification. 
Patients could also have been misclassified due to the mix of potassium measurements in serum and 
plasma. However, a study has shown that the difference in serum and plasma potassium 
measurements do not exceed 0.1 mmol/L when referring to the lower reference range.17 Therefore, 





Potassium concentrations outside the interval 4.1-4.7 mmol/L were associated with increased 90-day 
all-cause mortality risk in patients with hypertension treated with minimum two classes of 
antihypertensive drugs. 
7.2 Study II 
Persistent hypokalemia (<3.5 mmol/L) was frequent and associated with increased all-cause and 
cardiovascular death after an episode with potassium ≤3.7 mmol/L. Increase in potassium to levels 
>4.6 mmol/L in patients with initial hypokalemia or low normal potassium (≤3.7 mmol/L) was 
associated with increased all-cause mortality. Among patients with initial borderline hypokalemia, 
development of hypokalemia or hyperkalemia was associated with poor outcomes. 
7.3 Study III 
Overcorrection of hyperkalemia to levels <4.1 mmol/L was frequent and associated with increased 
all-cause mortality. Persistent hyperkalemia >5.0 mmol/L seemed to be associated with an increased 
risk of death as well. 
7.4 Study IV 
Combinations of thiazide diuretics with CCB, RASi, or BB were strongly associated with increased 
odds of hypokalemia within 90 days of treatment initiation, regardless of potassium supplementation 







Not only hypokalemia and hyperkalemia, but also low- and high- normal potassium concentrations 
were associated with increased short-term mortality risk. This suggests that a narrower potassium 
reference range should be aimed in patients with hypertension treated with combination 
antihypertensive therapy. Our study also suggested that potassium monitoring closely after 
combination therapy initiation might be relevant as many patients experienced dyskalemias. Future 
studies examining frequency of potassium measurement, potassium fluctuations over time, and effect 
of stringent potassium regulation on mortality and arrhythmia onset would supply, explain and put 
into perspective the observations made based on this study. These studies are important pieces in 
understanding the complexity of potassium homeostasis and its effects and their results can 
potentially save lives. 
8.2 Study II 
We were not able to report the initiatives medical doctors undertook after observing potassium levels 
≤3.7 mmol/L at the first measurement. However, our results emphasize the importance of aiming at 
potassium concentrations in the middle of the currently used RI and that overcorrection is associated 
with an increased risk of death (after an episode with potassium concentrations ≤3.7 mmol/L). 
Potassium concentrations in the middle of the normal reference interval are associated with good 
prognosis. Future research, investigating the effect of elevating potassium on mortality and other 
relevant clinical outcomes (hospitalization rate, arrhythmias) in patients with potassium 
concentrations between 3.5-3.7 mmol/L are warranted. 
Possibly, potassium supplementation, use of mineral receptor antagonists or thiazide-like diuretics 
instead of thiazide-type in patients with potassium concentrations ≤3.7 mmol/L could be of clinical 





Even though we were not able to report the initiatives physicians undertook when evaluating the 
results of first potassium measurement >4.6 mmol/L, our results emphasized the importance of 
potassium normalization after an episode with hyperkalemia and non-radical correction of 
hyperkalemia in patients with hypertension treated with combination antihypertensive therapy. Future 
studies should determine whether rapid reduction of potassium and stringent potassium control has a 
causal relation with (reduced) mortality and arrhythmic events. Generally, studies investigating the 
rate of correction and importance of immediately increasing/decreasing potassium in symptomatic 
and asymptomatic patients with dyskalemias are missing. 
8.4 Study IV 
Optimal management of hypertension is very important as numerous studies showed benefits both 
related to the risk of death but also to development of other cardiovascular conditions and health-
related quality of life. Most of the drugs used for management of high blood pressure can cause 
hypokalemia and hyperkalemia. In these days, where guidelines recommend polytherapy rather than 
monotherapy to lower blood pressure, awareness of the risk factors associated with potassium 
disturbances is also important.  Our study strongly suggested that any combination with thiazide 
diuretics was associated with high odds of hypokalemia within 90 days from combination therapy 
initiation, despite supplementation with potassium in a considerable proportion of the population. 
Therefore, we recommend close potassium monitoring in patients treated with thiazide diuretics. How 
close? It is difficult to define as evidence regarding the frequency of potassium monitoring when 
patients are administered diuretics is missing. A couple of small scale studies suggested that 
hypokalemia typically develops within 2-19 weeks from start diuretic treatment.91,92 Studies 
investigating the time frame where patients treated with diuretics are most vulnerable to develop 
hypokalemia are important both for the patient itself (to prevent adverse events) and for the healthcare 
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system (guidelines that specify the frequency of potassium monitoring). Another important aspect 
that should be focused on in future studies, is the risk of potassium disarrays associated to thiazide-
like and thiazide-type diuretics. In Denmark, thiazide-type diuretics are the most commonly used 
thiazide diuretics. Comparing our study with others, we believe that use of thiazide-like diuretics 
might be associated with fewer hypokalemia events. For example, in SPRINT trial (Systolic Blood 
Pressure Intervention Trial), hypokalemia occurred in 1.7% of the total patients regardless of 
treatment with indapamide. Yet, it occurred more frequently among patients treated with thiazides 
(3.0%) than in patients not taking thiazides (0.4%).93 Although, the lower frequency of hypokalemia 
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Appendix 1. List of antihypertensive drugs and corresponding ATC codes used to define hypertension 
ATC codes Name of drug 
C02A Antiadrenergic agents, centrally acting 
C02B Antiadrenergic agents, ganglion blocking 





C02L Antihypertensives and diuretics in combination 
C03AA Thiazides 
C03AB Thiazides and potassium in combination 
C03BA Sulfonamides 
C03BB Sulfonamides and potassium in combination 
C03C Loop diuretics 
C03DA Aldosteron antagonists 
C03DB Other potassium sparing agents 
C03EA Low-ceiling diuretics and potassium sparing agents 
C03EB High-ceiling diuretics and potassium sparing agents 
C03X Other diuretics 
C07A Beta-blockers 
C07B Beta-blockers and thiazides 
C07C Beta-blockers and other diuretics 
C07D Beta-blockers, thiazides and other diuretics 
C07FB Beta-blockers and calcium antagonists 
C07FX Beta-blockers and other combinations 
80 
 
C08C Selective calcium antagonists primarily with vascular 
effect 
C08D Selective calcium antagonists with direct cardiac effect  
C08E Non-selective calcium antagonists 
C08G Calcium antagonists and diuretics 
C09AA Angiotensin converting enzyme inhibitors 
C09BA Angiotensin converting enzyme inhibitors and diuretics 
C09BB Angiotensin converting enzyme inhibitors and calcium 
antagonists 
C09CA Angiotensin II antagonists  
C09DA Angiotensin II antagonists and diuretics 






Appendix 2. Definitions of comorbidities, procedures and concomitant medications based on 
different ICD-10, Nordic Classification of Surgical Procedures (NCSP), and ATC codes identified 






















Ischemic heart disease 
including myocardial 
infarction1 
I20-25 − 5 years KFNG, 
KFNA-E 
5 years − − 
Hemodialysis − − − BJFD20 5 years − − 
Atrial flutter or 
fibrillation 
I48 − 5 years − − − − 
Second- or third- 
degree 
atrioventricular block 









5 years − − − − 
Chronic liver disease B18, C22, 
K71-77 





E22.2 − 5 years − − − − 
Diabetes insipidus E23.2, 
N25.1 




− 5 years − − − − 
Hyperthyroidism DE050-59 − 5 years − − − − 
Addison disease E27.1 − 5 years − − − − 
Primary 
hyperaldosteronism 
E26.0 − 5 years − − − − 
Diabetes E10-14 − 5 years − − − − 
Any malignancy C00-99 − 5 years − − − − 
Hypertension DI11-15 − 5 years − − − − 
Heart failure I110, I130, 
I132, I42, 
I50, J81 









433-438 5 years − − − − 
82 
 
Acute kidney disease DN17, 
DN19, 
DR34 

























− − − − − − 
Inflammatory bowel 
disease (IBD) 


























Loop diuretics − − − − − C03C 90 days 
Non-steroidal anti-
inflammatory drugs 
− − − − −  M01A 180 days 
















































Macrolides − − − − − J01FA 30 days 




















Appendix 6. Time to potassium measurement and mortality within 90-days  
  
  
Days from index date/hypertension date to 
potassium measurement 
01–10 11–20 21–30 31–40 41–50 51–60 61–70 71–80 81 –90 
No. of patients  with serum potassium 
measurement 
8480 6733 6194 5426 4233 3870 3571 3264 3028 
Days from potassium measurement to 
death 
01–10 11–20 21–30 31–40 41–50 51–60 61–70 71–80 81 –90 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 11. Forestplot of univariable conditional logistic regression analysis for development of 
hypokalemia. Population matched on age, gender, renal insufficiency and time from combination 
therapy initiation to serum potassium measurement. The combination of calcium channel blockers 
with thiazide diuretics was used as reference. 
 
BB- Beta blockers 
CCB- Calcium channel blockers 
RASi- Renin-angiotensin system inhibitors 







Appendix 12. Forestplot of univariable conditional logistic regression analysis for development of 
hypokalemia. Population matched on age, gender, time from combination therapy initiation to 
serum potassium measurement, renal insufficiency, history with heart failure and history with 
ischemic heart disease/myocardial infarction. The combination of calcium channel blockers with 
thiazide diuretics was used as reference. 
 
BB- Beta blockers 
CCB- Calcium channel blockers 
RASi- Renin-angiotensin system inhibitors 
 “Potassium supplement” addressed supplementation as a single pill therapy with an 






Appendix 13. Forestplot of multivariable conditional logistic regression analysis for development of 
hypokalemia. Population matched on age, renal insufficiency, gender, and time from combination 
therapy initiation to serum potassium measurement, history with heart failure and history with 
ischemic heart disease/myocardial infarction. The model was adjusted for serum sodium, renal 
insufficiency, malignancy, IBD, diabetes and chronic liver disease. The combination of calcium 
channel blockers with thiazide diuretics was used as reference. 
 
 
BB- Beta blockers 
CCB- Calcium channel blockers 
RASi- Renin-angiotensin system inhibitors 
 “Potassium supplement” addressed supplementation as a single pill therapy with an 
antihypertensive and as an individual pill. 
102 
 
Appendix 14. Demographics of patients treated with combination antihypertensive therapy who did 





Age median(range) 65.0(19.0, 110.0) 
Sex Female 693325 (51.9) 
 
Male 643425 (48.1) 
Treatment combinations BB 44067 (3.3) 
 
BB+CCB 67329 (5.0) 
 
BB+RASi 117647 (8.8) 
 
BB+Thiazides+Potassium supplement 97645 (7.3) 
 
CCB+RASi 131292 (9.8) 
 
CCB+Thiazides+Potassium supplement 103378 (7.7) 
Other combination 412901 (30.9) 
RASi+Thiazides 200313 (15.0) 
RASi+Thiazides+Potassium supplement 162178 (12.1) 
Heart failure 100262 (7.5) 
IHD/MI 187983 (14.1) 
Atrial flutter/fibrillation 98578 (7.4) 
Stroke 83037 (6.2) 
COPD 62605 (4.7) 
Chronic kidney disease 24353 (1.8) 
Hemodialysis 1831 (0.1) 
Chronic liver disease 12745 (1.0) 
Diabetes 91554 (6.8) 
Inflammatory bowel disease 7691 (0.6) 
Hypothyroidism 11863 (0.9) 





IHD/MI- ischemic heart disease/myocardial infarction 
COPD- chronic obstructive pulmonary disease 
ICD- implantable cardioverter defibrillator 
BB- Beta blockers 
CCB- Calcium channel blockers 
RASi- Renin-angiotensin system inhibitors 
“Potassium supplement” addressed supplementation as a single pill therapy with an antihypertensive and not as an 
individual pill 
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Aims Diuretics and renin–angiotensin–aldosterone system inhibitors are central in the treatment of hypertension, but may
cause serum potassium abnormalities. We examined mortality in relation to serum potassium in hypertensive patients.
Methods
and results
From Danish National Registries, we identified 44 799 hypertensive patients, aged 30 years or older, who had a serum
potassium measurement within 90 days from diagnosis between 1995 and 2012. All-cause mortality was analysed ac-
cording to seven predefined potassium levels: ,3.5 (hypokalaemia), 3.5–3.7, 3.8–4.0, 4.1–4.4, 4.5–4.7, 4.8–5.0, and
.5.0 mmol/L (hyperkalaemia). Outcome was 90-day mortality, estimated with multivariable Cox proportional hazard
model, with the potassium interval of 4.1–4.4 mmol/L as reference. During 90-day follow-up, mortalities in the seven
strata were 4.5, 2.7, 1.8, 1.5, 1.7, 2.7, and 3.6%, respectively. Adjusted risk for death was statistically significant for
patients with hypokalaemia [hazard ratio (HR): 2.80, 95% confidence interval (95% CI): 2.17–3.62], and hyperkalaemia
(HR: 1.70, 95% CI: 1.36–2.13). Notably, normal potassium levels were also associated with increased mortality: K: 3.5–
3.7 mmol/L (HR: 1.70, 95% CI: 1.36–2.13), K: 3.8–4.0 mmol/L (HR: 1.21, 95% CI: 1.00–1.47), and K: 4.8–5.0 mmol/L
(HR: 1.48, 95% CI: 1.15–1.92). Thus, mortality in relation to the seven potassium ranges was U-shaped, with the lowest
mortality in the interval of 4.1–4.4 mmol/L.
Conclusion Potassium levels outside the interval of 4.1–4.7 mmol/L were associated with increased mortality risk in patients with
hypertension.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Serum potassium † Hypertension † Mortality
Introduction
The overall prevalence of hypertension in Europe is about 30–45%
of the total population1 with a treatment range from 11 to 66%.2
Many antihypertensive agents including diuretics, b-blockers,
angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin
receptor blockers (ARBs) can cause potassium disturbances3,4
and influence survival.5 Whereas the mechanisms that influence pa-
tient survival due to potassium disturbances are well known, little is
known about the optimal range of serum potassium in disease and
the levels associated with increased risk.6,7 The normal potassium
interval is defined based on apparently healthy individuals. The cur-
rent guidelines provide normal lower potassium limit from 3.5 to
3.8 mmol/L, while the upper limit is between 5.0 and 5.5 mmol/L.4,8,9
Well-defined hyperkalaemia and hypokalaemia in patients with
hypertension is known to increase the risk of death.5 In patients
with acute heart failure, potassium levels within the normal range
are associated with increased risk of death, highlighting that the
optimal level of potassium may differ from current definitions of
the normal range.10 Despite the widespread use of diuretics and
other drugs that influence potassium levels in patients with hyper-
tension, a search for optimal values of serum potassium has not
* Corresponding author. Tel: +45 53 14 88 24, Fax: +45 97 66 44 80, Email: lkcsmaria@yahoo.com; maria.krogager@rn.dk
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been performed.3,5,9 To address this issue, we used data from .40
000 individuals with hypertension to examine the relation between
serum potassium and all-cause mortality.
Methods
Databases
All residents in Denmark have a personal, unique, and permanent
civil registration number that enables individual linkage of administrative
registries. The Danish National Patient Registry consists of informa-
tion about all hospital admissions since 1978. At discharge, each hospi-
talization is registered with one primary and, if applicable, one or more
secondary diagnoses according to the International Classification of
Disease (ICD). Until 1994, the 8th revision (ICD-8) was in use and
from 1994 onwards the 10th revision (ICD-10). The National Register
for Medicinal Statistics includes all dispensed prescriptions from Danish
pharmacies since 1995 based on the Anatomical Therapeutic Chemical
System (ATC). As the healthcare system is state financed and partly re-
imburses drug costs, all Danish pharmacies are legally required to regis-
ter all dispensed drug prescriptions, providing a valid and accurate
register. Date of death, date of birth, and vital status were obtained
from the Danish Register of Causes of Death and the Central Personal
Registry. Blood test results were obtained from electronic registries of
laboratory data, and we had access to data covering 1.5 million
individuals.
Study population
Hypertension was primarily defined by the use of at least two concomi-
tant antihypertensive drugs in two concomitant quarters. Patients en-
tered the study in the second quarter. This definition has previously
been validated: positive predictive value 80% and specificity 94.7%.1,11
We performed two sensitivity analyses where we selected the popula-
tion based on ICD codes and where we excluded patients receiving loop
diuretics. The first serum potassium measurement within 90 days of
antihypertensive treatment was selected. To avoid extreme outliers, pa-
tients with potassium levels ,2.9 mmol/L and .5.8 mmol/L were ex-
cluded. Patients under the age of 30 years were excluded because it is
unlikely that this group would have essential hypertension. The patients
were censored on 31 December 2012 or after 90-day follow-up. Pa-
tients with serum potassium measurements up to 90 days after dual
single-pill antihypertensive drug treatment were included in the study.
The outcome of the study was 90-day mortality from the date of serum
potassium measurement.
Co-morbidities and drugs
The statistical analyses were performed on patients stratified in groups
by the following potassium levels: ,3.5, 3.5–3.7, 3.8–4.0, 4.1–4.4,
4.5–4.7, 4.8–5.0, and .5.0 mmol/L. Hypokalaemia was defined as
potassium ,3.5 mmol/L and hyperkalaemia as .5.0 mmol/L. Serum
potassium interval of 4.1–4.4 mmol/L was used as reference for statis-
tical analysis. The reference interval was chosen based on the restricted
cubic splines results, and also other analysis, which confirmed that the
lowest mortality risk was found in this range.
Besides age and gender, the following conditions present before
the date of hypertension were assessed and used as covariates in the
analysis: chronic obstructive pulmonary disease (ICD-8: 491, 492;
ICD-10: J42–44), stroke (ICD-8: 433–438; ICD-10: I61, I62, I63, I64,
DG458, DG459), acute myocardial infarction (ICD-10: I21), atrial
fibrillation (ICD-10: I48), heart failure (ICD-10: I50), and diabetes.12,13
Diabetes was defined as more than two dispensed prescriptions of
glucose-lowering drugs (ATC code A10; insulin or oral hypoglycaemic
agents), because patients with diabetes were not necessarily admitted
to hospital with this specific diagnosis.10,14– 16 Serum creatinine was ob-
tained within a week of serum potassium measurement. Patients with
renal insufficiency and missing creatinine levels were excluded. Renal in-
sufficiency was defined by a serum creatinine level: (i) .105 mmol/L for
men ,70 years, (ii) .125 mmol/L for men .70 years, (iii) .90 mmol/L
for women ,70 years, and (iv) .105 mmol/L for women .70
years.17,18 A total of 1857 patients did not have a serum creatinine meas-
urement. Serum sodium measured same day as serum potassium was
also identified.
Patients who prior to the administration of two concomitant antihy-
pertensives were diagnosed with acute (ICD-10: DN17, DN19, DR34)
chronic kidney disease, including proteinuria (ICD-10: DN02–08,
DN11–12, DN14, DN18–19, DN26, DN158–160, DN162–164,
DN168, DN313, DQ612–613, DQ615, DQ619, DE102, DE112,
DI120, DM300, DM319, DM321B) or primary hyperaldosteronism
(ICD-10: DE260), were also excluded.
We included the five most prescribed antihypertensive single-pill
drug combinations in the multivariable analysis: ACEIs/ARBs and
thiazide diuretics; ACEIs/ARBs and b-blockers; ACEIs/ARBs and calcium
channel blockers; ACEIs/ARBs, thiazide diuretics, and potassium
supplements; and b-blockers, thiazide diuretics, and potassium supple-
ments. The remaining possible combinations were categorized as other
combinations of antihypertensive medication. The combination of
ACEIs/ARBs with thiazide diuretics and potassium supplements was
used as reference for statistical analysis. The following medications
(ATC codes) were identified: renin–angiotensin system inhibitors
C09; calcium channel blockers C08; b-blockers C07; diuretics C03; anti-
adrenergic drugs C02A, C02B, and C02C; and other antihypertensives
C02DA, C02DB, C02DD, C02DG, and C02L. Apart from medication
for hypertension, we have also included potassium supplements
(ATC: A12B) in the multivariable statistical analysis.
Statistical analysis
Kaplan–Meier cumulative mortality curves were plotted for the seven
preselected potassium intervals to illustrate trends in mortality. Cox
proportional hazard regression models were used to determine
the risk of death in hypertensive patients with different potassium inter-
vals, adjusted for all covariates. To validate this statistical model, the
three Cox proportional hazard model assumptions were assessed: pro-
portionality, linearity, and interaction. As linearity assumption had not
been fulfilled regarding the continuous variable age, we predefined
four age intervals: 30–50 years, 51–70 years, 71–80 years, and .80
years. Age interval of 50–70 years was used as reference.
The association of potassium with mortality was also assessed using
restricted cubic splines with knots at the 10th, 25th, 50th, 75th, and 90th
percentiles of potassium.
Relative risks are presented as hazard ratios (HR) with 95%
confidence intervals (95% CI). P-values of ,0.05 were considered sig-
nificant. Analyses were performed with SAS (version 9.4, SAS Institute,




In the period 1995–2012, we identified 44 799 hypertensive
patients that had a potassium measurement within 90 days from
diagnosis. The average age in the population was 67.1 (+12.6)
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years. The characteristics of the population, reported according to
the seven potassium levels, are presented in Table 1. No significant
difference in gender distribution was observed within the total
population. Women were overall more susceptible to hypokal-
aemia, whereas men more often had hyperkalaemia. The overall po-
tassium distribution was mean 4.20 mmol/L and median 4.2 mmol/L.
The 25th and 75th percentiles for potassium were 3.92 and
4.5 mmol/L, respectively. Mean serum sodium was 139.7 (+3.9).
Of the patients, 5486 were prescribed antidiabetic drugs and
1% were treated with insulin. The other co-morbid conditions
such as atrial fibrillation, heart failure, and acute myocardial
infarction were present in a rate of 10% each.
The major antihypertensive drug combinations were ACEIs/ARBs
combined with thiazides and potassium supplement 13.5%; ACEIs/
ARBs with b-blockers 12%; ACEIs/ARBs with thiazide diuretics
11.4%; b-blockers combined with thiazides and potassium supple-
ment 7.4%; and ACEIs/ARBs with calcium channel blockers 7%. In
total, 21 494 patients were prescribed potassium supplements.
Serum potassium level was measured 36.6 (+25.6) days, on aver-
age, after administration of minimum two concomitant antihyper-
tensive drugs. Supplementary material online, S1 illustrates that in
the first 45 days from dual antihypertensive therapy initiation,
most potassium measurements are effectuated (65.1%) and most
events (death) registered (72.9%). As there can be seen in Supple-
mentary material online, S2, 74.8% of the total population was admi-
nistered diuretics and 70% ACEIs/ARBs. There can also be observed
that the administration of diuretics in the low normal potassium
level was slightly higher than the administration of ACEIs/ARBs.
Likewise, ACEIs/ARBs prescription was marginally higher than
diuretic prescription in the upper potassium interval.
Survival analysis
Survival curves are illustrated in Figure 1. Of the patients, 866 (1.9%)
died during the 90-day follow-up. Mortality in the seven strata
was low: 4.5, 2.7, 1.8, 1.5, 1.7, 2.7, and 3.6%, respectively. The highest
90-day mortality rates were observed in 2005 and 2010 with 80
and 83 observations, respectively. Univariate HRs of each potassium
level are shown in Figure 2. The lowest mortality risk was observed
in the interval of 4.1–4.4 mmol/L, while hypo- and hyperkalaemia
were associated with increased mortality. Risk of all-cause mortality
was also increased in potassium intervals: 3.5–3.7 and 4.8–
5.0 mmol/L. Likewise, we observed a trend towards excess mortal-
ity in the intervals of 3.8–4.0 and 4.5–4.7 mmol/L.
The results of the multivariable analysis with potassium 4.1–
4.4 mmol/L as reference are shown in Figure 3. After adjusting the
model for age, sex, biologically relevant co-morbidities, and con-
comitant medication, the mortality remained significantly increased
for all potassium ranges outside the interval of 3.8–4.7 mmol/L.
Being a female or over the age of 70 years were overall associated
with increased mortality. Patients with co-morbid conditions such
as chronic obstructive pulmonary disease, atrial fibrillation, heart
failure, and stroke also had an increased risk of death. Considering
the different antihypertensive drug combinations, we observed a
trend that ACEIs/ARBs in combination with thiazide diuretics
were a safe treatment (HR: 0.65, 95% CI: 0.42–1.01, P ¼ 0.05).
However, the combination of b-blockers with thiazide diuretics
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mortality risk (HR: 1.46, 95% CI: 1.03–2.08, P ¼ 0.03). Moreover,
other single-pill antihypertensive drug combinations than the top
five included in the adjusted model were significantly associated
with increased risk of death, with HR 1.85.
The U-shaped restricted cubic splines curve shown in Figure 4
indicated that the lower and the higher the serum potassium level,
the greater the mortality risk. Additionally, the splines curve indi-
cated differences in risk within the normal potassium ranges, where
potassium interval of 4.1–4.4 mmol/L was associated with the
lowest risk of death.
Other analyses
Three additional sensitivity analyses were applied to verify the initial
findings. The results of these analyses are illustrated in Table 2. First,
we selected our hypertensive population based on ICD codes from
the National Patient Registry, and we included in the analysis
the patients who received minimum two concomitant antihyper-
tensive drugs in the interval of 90 days before the diagnosis or
30 days after the diagnosis. Potassium interval of 3.8–4.0 mmol/L
was no longer significantly associated with increased risk, although
with a clear tendency towards our initial findings (HR: 1.14, 95% CI:
0.98–1.32, P ¼ 0.10).
Second, we excluded patients who were administered loop diure-
tics according to the Prescription Registry as loop diuretics could in-
dicate heart failure. This analysis also showed that potassium level of
3.8–4.0 mmol/L was not significantly associated with the increased
risk of death, although evidently with the same overall trends as in
our initial findings (HR: 1.24, 95% CI: 0.94–1.64, P ¼ 0.12).
Third, we excluded patients who, prior hypertension date,
were diagnosed with myocardial infarction or heart failure as
both could be treated with medication used for hypertension.
This analysis showed that potassium levels outside the interval
of 4.1–4.7 mmol/L were associated with increased mortality risk.
Discussion
This study analysed the short-time mortality risk in relation to
different potassium intervals in hypertensive patients administered
various classes of blood-pressure-lowering drugs. The major finding
was that even mild deviations within the normal potassium range
(3.5–5.0 mmol/L) were associated with increased mortality.
Although it was expected that hypo- and hyperkalaemia would be
associated with increased risk of death, it was unexpected that three
normal potassium levels (K: 3.5–3.7, 3.8–4.0, and 4.8–5.0 mmol/L)
were also associated with a significantly increased mortality in
hypertensive patients.
We considered the time frame of potassium measurement within
90 days from start of antihypertensive treatment optimal for analys-
ing the acute mortality risk in patients with hypertension for two
reasons. First, Mcdowell and Ferner19 showed in a review about
monitoring of hypertensive patients for adverse drugs reactions
that the peak follow-up time of potassium and creatinine was
3 months and 1 year after treatment initiation, respectively. Second,
Podrid7 illustrated in a review that potassium concentrations were
directly related to the dosage of the administered diuretic. Low po-
tassium can be observed from 4 to 40 weeks after treatment with
diuretics in patients with hypertension. Moreover, Supplementary
material online, S1 reveal that the majority of the population had
a potassium measurement in the first 45 days (65.1%) and that
most of the patients deceased (72.9%) in the same timeframe. How-
ever, methodologically, it would not have been appropriate to re-
duce the follow-up time as a considerable number of patients did
not have their potassium measured and we would have missed
Figure 1 Kaplan–Meier analysis of the survival probability
among the different potassium intervals. n ¼ 44 799.
Figure 2 All-cause mortality in hypertensive patients stratified by potassium intervals (90-day follow-up). n ¼ 44 799. Reference interval
represented by the interval K: 4.1–4.4 mmol/L.






/eurheartj/article/38/2/104/2965186 by guest on 03 Septem
ber 2020
27.1% of the events. Furthermore, a longer follow-up time would
have been a great bias, as data showed a trend in less potassium
measurement and less events over time. In as such, within a window
period of 90 days from hypertension treatment, we intended to
register both the immediate and the slow onset potassium disarrays.
It is important to acknowledge that all patients have been treated
with two antihypertensive drugs for two concomitant quarters
(180 days) before the first potassium measurement.
As for the definition of hypertension, Olesen et al.11 have vali-
dated the model of identifying hypertensive patients according to
blood-pressure-lowering drug prescriptions. Nevertheless, we per-
formed a sensitivity analysis where we attempted to identify major
difference in identification of hypertensive population based on ICD
codes vs. pharmacological treatment. We did not observe any major
difference in the association of the defined potassium intervals and
mortality risk. Moreover, the combination of ACEIs/ARBs with loop
diuretics can indicate heart failure and not hypertension.1 For this
reason, we completed a second sensitivity analysis where patients
with loop diuretic prescription were excluded. This analysis did
not show any considerable difference in results when compared
with the initial analysis. Additionally, we performed a third analysis
where patients with history of myocardial infarction and heart fail-
ure were excluded. This was because combination of ACEIs with
b-blockers could indicate one of the above mentioned conditions
and not hypertension.20,21 This analysis did not show major differ-
ence when compared with the other two sensitivity analysis, or
main analysis. Overall, these analyses showed almost identical re-
sults to our primary analysis, with small variations in statistical signifi-
cance probably related to fewer individuals in each potassium
interval group. All these analyses indicated that serum potassium
.4.0 and ,4.7 mmol/L is optimal in hypertensive patients.
To our knowledge, few, if any, studies3,9 have investigated which
potassium interval is the safest in hypertensive patients; most studies
have analysed the effect of different classes of antihypertensive
drugs on potassium homeostasis, mortality, and cardiovascular
and non-cardiovascular events. Alderman et al. demonstrated that
patients are more prone to hypokalaemia if treated with chlorthali-
done compared with amlodipine or lisinopril, and that hypokalaemic
patients have a higher mortality risk than do those with normokalae-
mia.12 Moreover, Ikram mentioned in his article ‘a crossover study
design in hypertensive patients with coronary disease’ that mild de-
grees of hypokalaemia induced by thiazide diuretics increased the
tendency to arrhythmia when compared with normokalaemia on
a potassium-sparing diuretic.22 –24 These findings are in agreement
with our study. We observed increased all-cause mortality in
hypokalaemic patients, and that thiazides in combination with
ACEIs/ARBs seemed to be particularly safe for hypertensive patients
when compared with the reference (ACEIs/ARBs combined with
Figure 3 All-cause mortality in hypertensive patients stratified by potassium intervals (90-day follow-up). n ¼ 44 799. Model adjusted for cov-
ariates. Reference interval represented by the interval K: 4.1–4.4 mmol/L; and single-pill combination of angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers, thiazide diuretics, and potassium supplements. ACEIs/ARBs, angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers.
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thiazide diuretics and potassium supplements). Alderman et al. also
demonstrated that ACEIs increase the risk of elevated potassium
and that this patient group had ‘a significantly increased risk of com-
bined cardiovascular disease compared with normokalaemics’. Simi-
larly, our study demonstrated that hyperkalaemic patients are
associated with increased mortality risk compared with normoka-
laemic patients, and that patients in this group are characterized
by a higher administration rate of ACEIs/ARBs than are hypokalaem-
ic and normokalaemic patients. Nevertheless, several studies and
guidelines recommend dual therapy of ACEIs/ARBs with calcium
channel blockers, diuretics, or b-blockers.1,25,26 This statement is
strongly supported by our study that showed that single-pill
combination of ACEIs/ARBs with b-blockers and thiazide diuretics
was associated with decreased mortality risk, in spite of insignificant
P-values.
The study by Macdonald and Struthers was the only study/review
we identified that contained exact recommendations for a potas-
sium interval in patients with hypertension.9 The authors indicated
that it is favourable for hypertensive patients to maintain potassium
between 3.5 and 5.0 mmol/L. This was based on studies that evalu-
ate the link between hypokalaemia and development of ventricular
arrhythmias and sudden cardiac death. However, most of the cited
studies did not directly examine the relationship between serum
potassium and mortality in hypertensive patients.
Overall, we were unable to identify any studies that provide direct
evidence to select optimum levels of serum potassium in disease
or health. Here, we demonstrate a significantly increased risk of
death among hypertensive patients with serum potassium ,4.1
or .4.7 mmol/L.
Study limitations
The limitations largely relate to the observational nature of the
study. However, the Danish National Health registries contain
uniquely detailed information, and we were able to extract reliable
data on co-morbid illnesses and concomitant medication, as well as
potassium measurements and date of death, overall strengthening
the reliability of our findings. All factors that were considered pos-
sible confounders were included in the Cox multivariable analysis.
Limitations of this study are represented by the lack of informa-
tion regarding the cause of death. In certain circumstances, it might
Figure 4 Restricted cubic splines showing the adjusted hazard
ratios for all-cause mortality as a function of potassium concentra-
tion. Knots at the 10th, 25th, 50th, 75th, and 90th percentiles of
potassium. Model adjusted for age, sex, chronic obstructive pul-
monary disease, stroke, acute myocardial infarction, atrial fibrilla-
tion, heart failure, diabetes mellitus, potassium supplement,
angiotensin-converting enzyme inhibitors/angiotensin receptor
blockers in combination with thiazides, angiotensin-converting en-
zyme inhibitors/angiotensin receptor blockers in combination with
calcium channel blockers, angiotensin-converting enzyme inhibi-
tors/angiotensin receptor blockers in combination with b-blockers,
b-blockers in combination with thiazides and potassium supple-
ments, and other single-pill antihypertensive drug combinations.
n ¼ 44 799. This figure shows an approximation of the function
relating serum potassium to the hazard rate of death, and should
not be interpreted with respect to some reference.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Sensitivity analysis 1 (hypertensive patients found according to International Classification of Disease codes)
and sensitivity analysis 2 (patients with loop diuretic prescription excluded from main analysis) and sensitivity analysis 3





on ICD codes (n 5 26 126)
Patients with loop diuretic prescription
were excluded (n 5 35 393)
Patients with an acute myocardial
infarction or heart failure diagnosis
before hypertension were excluded
(n 5 35 827)
HR Low 95% High 95% P HR Low 95% High 95% P HR Low 95% High 95% P
2.9–3.4 1.91 1.63 2.24 ,0.01 3.49 2.43 5.00 ,0.01 2.99 2.21 4.06 ,0.01
3.5–3.7 1.49 1.28 1.74 ,0.01 2.03 1.48 2.79 ,0.01 1.89 1.44 2.48 ,0.01
3.8–4.0 1.14 0.98 1.32 0.10 1.24 0.94 1.64 0.12 1.31 1.04 1.66 0.02
4.1–4.4 1 Reference 1 Reference 1 Reference
4.5–4.7 1.18 0.98 1.43 0.07 0.95 0.69 1.30 0.74 1.18 0.91 1.53 0.22
4.8–5.0 1.38 1.07 1.78 0.01 1.50 1.01 2.22 0.04 1.85 1.34 2.55 ,0.01
5.1–5.8 2.20 1.66 2.91 ,0.01 1.89 1.11 3.24 0.02 2.13 1.37 3.29 ,0.01
Model adjusted for covariates. Reference interval represented by the interval K: 4.1–4.4 mmol/L.
All-cause mortality in hypertensive patients stratified by potassium intervals (90-day follow-up).
ACEIs/ARBs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers.
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be difficult to determine the primary cause of death when a patient
can be attributed one or more codes in situations where autopsy is
missing.
As the Danish National Health registries do not contain reliable
diagnostic codes for differentiating whether hypertension was diag-
nosed in hospital vs. general practitioner, we used an alternative mo-
dality based on a validated algorithm for identifying patients with
hypertension. Despite the high predictive value and specificity of
this method, misclassification of some patients as hypertensive
could occur. With regard to the definition of diabetes, we could en-
counter similar problems as with hypertension. Patients with dia-
betes who were treated by their general practitioner and never
hospitalized do not have diabetes diagnostic codes available. There-
fore, we considered that more than two prescriptions of glucose-
lowering drugs may increase the predictive value in our cohort.
However, misclassification cannot be excluded.
Furthermore, our population may not extend to other popula-
tions, which can lead to difficulty in reproducing these results world-
wide. Despite the fact that we performed three sensitivity analyses
to adjust for major confounders, we cannot exclude a possible effect
of unmeasured confounders. Additionally, the characteristics of the
patients with hypertension, who had a serum potassium measure-
ment within 90 days from dual single-pill therapy, may be different
from the hypertensive patients who did not have a potassium meas-
urement in this time interval. Moreover, it is discussable whether the
use of the first serum potassium measurement within the 90 days of
antihypertensive treatment was optimal for the analysis of 90-day
mortality. However, we observed decrease in both potassium mea-
surements and death rate in time. Last but not least, we cannot
affirm whether mortality is increased due to the influence of
potassium influence on myocardial membrane potential or it is a
marker of other processes.
Conclusion
In conclusion, our results strongly indicate that serum potassium
levels ,4.1 or .4.7 mmol/L are associated with a significantly
increased mortality in hypertensive individuals.
Clinical implications
This study indicates that low- and high-normal potassium levels may
be associated with increased risk of death, which suggests that a nar-
rower normal interval might improve outcome in patients with
hypertension. Most drugs against hypertension influence in some
way potassium homeostasis. Therefore, monitoring soon after the
onset of medication would probably be relevant to achieve stable
potassium levels and improve survival. Future studies that focus
on frequency of potassium measurement, potassium fluctuations
over time, and effect of potassium regulation on mortality can surely
complement this study’s findings.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Impact of plasma potassium normalization
on short-term mortality in patients with
hypertension and hypokalemia or low
normal potassium
Maria Lukács Krogager1* , Peter Søgaard1, Christian Torp-Pedersen2, Henrik Bøggild3,4, Christina Ji-Young Lee2,5,
Anders Bonde5, Jesper Q. Thomassen6, Gunnar Gislason7,8,9, Manan Pareek2,10,11 and Kristian Kragholm1,4,12
Abstract
Background: Hypokalemia is common in patients treated with antihypertensive drugs, but the impact of correcting
hypokalemia is insufficiently studied. We examined the consequences of hypokalemia and borderline hypokalemia
correction in patients with hypertension.
Methods: We identified 8976 patients with hypertension and plasma potassium concentrations ≤3.7 mmol/L within
100 days from combination antihypertensive therapy initiation. The first measurement between 6 and 100 days after
the episode with potassium ≤3.7 mmol/L was retained. We investigated all-cause and cardiovascular mortality
within 60-days from the second potassium measurement using Cox regression. Mortality was examined for seven
predefined potassium intervals derived from the second measurement: 1.5–2.9 mmol/L (n = 271), 3.0–3.4 mmol/L
(n = 1341), 3.5–3.7 (n = 1982) mmol/L, 3.8–4.0 mmol/L (n = 2398, reference), 4.1–4.6 mmol/L (n = 2498), 4.7–5.0 mmol/
L (n = 352) and 5.1–7.1 mmol/L (n = 134).
Results: Multivariable analysis showed that potassium concentrations 1.5–2.9 mmol/L, 3.0–3.4 mmol/L, 4.7–5.0
mmol/L and 5.1–7.1 mmol/L were associated with increased all-cause mortality (HR 2.39, 95% CI 1.66–3.43; HR 1.36,
95% CI 1.04–1.78; HR 2.36, 95% CI 1.68–3.30 and HR 2.62, 95% CI 1.73–3.98, respectively). Potassium levels <3.0
and > 4.6 mmol/L were associated with increased cardiovascular mortality. The adjusted standardized 60-day
mortality risks in the seven strata were: 11.7% (95% CI 8.3–15.0%), 7.1% (95% CI 5.8–8.5%), 6.4% (95% CI 5.3–7.5%),
5.4% (4.5–6.3%), 6.3% (5.4–7.2%), 11.6% (95% CI 8.7–14.6%) and 12.6% (95% CI 8.2–16.9%), respectively.
Conclusions: Persistent hypokalemia was frequent and associated with increased all-cause and cardiovascular
mortality. Increase in potassium to levels > 4.6 mmol/L in patients with initial hypokalemia or low normal potassium
was associated with increased all-cause and cardiovascular mortality.
Keywords: Hypokalemia, Borderline hypokalemia, Hypokalemia correction, Mortality, Low potassium.
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 Correcting plasma potassium concentrations ≤3.7
mmol/L to levels between 3.5–4.6 mmol/L was
associated with improved short-term prognosis
What is relevant?
 Increased mortality risk was observed in patients
who initially had borderline hypokalemia, partly
because they developed hypokalemia. This
emphasizes that potassium supplementation might
be relevant in patients with low normal potassium
concentrations
 Correcting hypokalemia and borderline hypokalemia
shortly was associated with good prognosis
 Low potassium concentrations have previously been
associated with arrhythmogenesis and increased
mortality risk in patients with hypertension.
Summary
In this register based study we investigated the impact
of correcting hypokalemia and borderline hypokalemia
on 60-day mortality among 8976 patients treated with
combination antihypertensive therapy. We observed
that: (1) persistent hypokalemia was common and asso-
ciated with increased all-cause and cardiovascular mor-
tality; (2) Increase in potassium to levels > 4.6 mmol/L in
patients with initial hypokalemia or low normal potas-
sium was associated with increased all-cause and cardio-
vascular mortality; (3) Among patients with borderline
hypokalemia initially, development of hypokalemia or
hyperkalemia was associated with increased mortality
risk; (4) Correcting hypokalemia associated with in-
creased survival.
Background
Several common clinical conditions and drugs are
known to cause or precipitate hypokalemia [1]. Among
patients with hypertension, thiazides are the antihyper-
tensive drugs most frequently associated with hypokal-
emia [2–4].
We recently demonstrated a U-shaped relationship be-
tween potassium levels and mortality among patients
with hypertension. We observed an increased mortality
risk even in patients with low and high normal serum
potassium concentrations, suggesting a narrower than
previously thought normal interval for potassium of 4.1–
4.7 mmol/L. [5] However, at present there is no evidence
regarding the consequences of potassium normalization
in patients with hypertension and hypokalemia. There-
fore, it is essential to examine how correction and even
overcorrection of hypokalemia affect prognosis in pa-
tients with hypertension.
Using Danish national registers, we investigated the
60-day mortality among patients with hypertension and
hypokalemia or low normal potassium concentrations,
according to their subsequent plasma potassium concen-
trations measured within 6–100 days following the initial
episode with low potassium levels.
Methods
Data sources
In Denmark, a unique and personal identification num-
ber is allocated to all individuals at the time of birth or
immigration. This unique identifier allows linkage of
health and administrative data at the individual level [6]
and ensures nearly complete follow-up. We used anon-
ymized data from five different registers made available
by Statistics Denmark after central encryption of the
unique identifiers [7]. An overview of the registers used
in this study is available in Supplementary Table S1. In
Denmark, register-based studies using anonymized data
provided by Statistics Denmark are not warranted ap-
proval from the ethics committee.
Study population
We defined hypertension as redemption of minimum
two antihypertensive agents in two consecutive quarters.
This definition has previously been validated [8]. Pa-
tients entered the present study in the second quarter,
referred to as the date of hypertension. An overview of
the Anatomical Therapeutic Chemical Classification
System (ATC) codes used to identify patients with
hypertension is available in Supplementary Table S2. We
required a plasma potassium measurement ≤3.7 mmol/L
within 100 days from the date of hypertension for inclu-
sion. The first measurement within this time interval
was retained and referred to as the first potassium meas-
urement (K1). The second potassium measurement (K2)
was identified in the interval 6–100 days from K1 and
the first draw within this timeframe was retained. We
did not include potassium concentrations within 1–5
days from K1 as, potassium disarrays are usually cor-
rected within a few days, regardless of the strategies ap-
plied. Patients below 18 years of age were excluded from
the study. Supplementary Figure S1 illustrates the popu-
lation flowchart.
Comorbidities and medication
We identified comorbidities and medications regarded
as confounders when studying the association between
changes in potassium levels and short-term mortality.
The following comorbidities dated up to 5 years before
the index date (K2 date) were identified: hospitalization
for heart failure, ischemic heart disease, stroke, chronic
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obstructive pulmonary disease, chronic liver disease, dia-
betes mellitus, inflammatory bowel disease and malig-
nancy. Furthermore, patients with a past history of
primary adrenal insufficiency, primary hyperaldosteron-
ism, and diabetes insipidus were excluded. The Inter-
national Classification of Disease (ICD) codes used to
identify above-mentioned comorbidities are shown in
Supplementary Table S3. We used the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation
[9] to calculate renal function, and an estimated glom-
erular filtration rate (eGFR) < 30mL/min/1.73 m2 de-
scribed significant renal insufficiency. Patients were
excluded if no creatinine concentrations were available
the same day as or within a week from the index date.
Patients with missing serum sodium measurements on
the index date were also excluded.
Prescriptions redeemed up to 90-days before the
index date were identified for the following drugs: po-
tassium supplements, non-steroidal anti-inflammatory
drugs, corticosteroids, laxatives, xanthines, and anti-
microbials. See Supplementary Table S3 for relevant
ATC codes.
Exposure variable
Serum and plasma measurements yield similar results,
but for serum samples there is a risk of contamination
with potassium from burst platelets during coagulation
in the range of 0.1–0.5 mmol/L due to non-standard
sample handling [10]. Therefore, we only used plasma
potassium measurements.
There is not a consensus on the normal plasma potas-
sium interval, as it can vary from population to popula-
tion. Supplementary Table S4 gives an overview on the
three most used reference intervals in serum and plasma
originating from different populations. We defined hypo-
kalemia as plasma potassium concentrations below 3.5
mmol/L and borderline hypokalemia as potassium levels
within the interval 3.5–3.7 mmol/L. Hyperkalemia was
defined as potassium levels above 4.6 mmol/L. [11] For
K2, seven predefined potassium intervals were
constructed: 1.5–2.9 mmol/L, 3.0–3.4 mmol/L, 3.5–3.7
mmol/L, 3.8–4.0 mmol/L, 4.1–4.6 mmol/L, 4.7–5.0
mmol/L and 5.1–7.1 mmol/L. Plasma potassium interval
K: 3.8–4.0 mmol/L was used as the reference for statis-
tical analyses. We chose this interval as the reference
group because it had one of the largest number of pa-
tients and lowest mortality rate.
Outcome
The primary outcome was all-cause mortality within 60
days from K2. The secondary outcome was presumed
cardiovascular death within 60 days from K2.
Statistical analyses
Categorical variables were presented as counts and per-
centages, and continuous variables as median with corre-
sponding 25th and 75th percentiles. Differences between
variables were compared using chi-squared and Kruskal-
Wallis tests, as appropriate.
To illustrate survival probability, Kaplan Meier curves
were plotted for the seven potassium intervals. A re-
stricted cubic spline curve was constructed to investigate
the relationship between potassium as a continuous vari-
able and absolute mortality risk in an age, sex, comor-
bidity and drug standardized population.
Cox proportional hazard modeling was used to analyze
the association between the seven predefined potassium
intervals and 60-day all-cause and presumed cardiovas-
cular mortality. Based on the Cox regression principle,
we modelled an average effect to estimate the 60-day ab-
solute risk of all-cause mortality, with potassium interval
3.8–4.0 mmol/L as reference.
The multivariable model was adjusted for: age, sex,
serum sodium, renal insufficiency, malignancy, heart fail-
ure, chronic liver disease, chronic obstructive pulmonary
disease, diabetes mellitus, stroke, atrial flutter/fibrilla-
tion, ischemic heart disease, inflammatory bowel disease,
antihypertensive therapy, corticosteroids, antimicrobials,
non-steroidal anti-inflammatory drugs, xanthines, laxa-
tives, and potassium supplements. The proportional
hazard assumption was tested by plotting Schoenfeld re-
siduals and was not violated. Interactions on mortality
were tested by comparing the likelihood ratio of the Cox
regression model with and without the interaction term.
The following variables were tested for interaction with
plasma potassium on mortality: age, sex, and renal insuf-
ficiency. A two-sided p-value < 0.01 was considered
statistically significant for interactions. We found no sta-
tistically significant interactions. For other analyses, a
two-sided p-value < 0.05 was considered statistically sig-
nificant. Linearity of age on mortality was also assessed
through a likelihood ratio test comparing a linear
description with a categorical one. Age was found to
violate linearity and was included as a categorical
variable with five levels, using cut-off values from every
20th percentiles (55, 64, 72, 79 and 101 years). Hazard
ratios (HR) and absolute risks (AR) were estimated with
95% confidence intervals (95% CI). All data management
and analyses were performed using SAS, version 9.4 and
R, version 3.5.0 [12].
Results
Demographics
We identified 8976 patients treated with combination
antihypertensive therapy who had potassium concentra-
tions ≤3.7 mmol/L within the first 100 days from com-
bination therapy initiation. Baseline characteristics for
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the cohort stratified on the seven predefined K2 intervals
are presented in Table 1. Females accounted for 53% of
the total population and median age was 68.3 years
(range 18.2–100.8 years). Of the patients with borderline
hypokalemia at K1, 13% developed hypokalemia and
5.7% hyperkalemia at K2. As for patients with hypokal-
emia at K1, we observed that 28.5% remained hypokal-
emic at the second blood draw and 4.8% developed
hyperkalemia. Approximately half of the population was
hospitalized at K1 and four fifths at K2. See supplemen-
tary Figure S2 displaying the distribution of K1, average
of potassium measurements drawn within 1–5 days from
K1, and K2. A low number of patients (n = 572) had
renal insufficiency at the time of second potassium draw.
Median time from K1 to K2 was 22 days (range: 6–100
days). As for diuretic treatment, thiazides were common
in patients with potassium concentrations ≤3.7 mmol/L,
whereas loop diuretics were more common among pa-
tients with high potassium levels. Thiazide-like diuretics
accounted for 4.4% of the total prescriptions of
thiazides.
Demographics stratified on survival status showed that
age, renal insufficiency, lower sodium concentrations,
hospitalization at the time K1, prior history of malig-
nancy, chronic liver disease, chronic obstructive pul-
monary disease, atrial fibrillation/atrial flutter, heart
failure, and stroke were predominant among the de-
ceased (Supplementary Table S5).
60-day survival after the second potassium measurement
During 60-day follow-up after K2, 627 (7.0%) patients
died, 331 from a cardiovascular cause. Mortality in the
seven strata was: 14.4, 7.0, 6.3, 5.2, 6.7, 13.6 and 21.6%,
respectively. The restricted cubic spline curve revealed a
U-shaped relationship between potassium and mortality
(Fig. 1).
The results of the multivariable Cox regression, with
plasma potassium 3.8–4.0 mmol/L as the reference
group are shown in Fig. 2. All-cause mortality was sig-
nificantly increased in patients with hypokalemia (1.5–
2.9 mmol/L HR 2.39, 95% CI 1.66–3.43 and 3.0–3.4
mmol/L HR 1.36, 95% CI 1.04–1.78) when compared
with the reference. We observed a trend towards
increased mortality in patients with borderline hypokal-
emia and with potassium levels within the interval 4.1–
4.6 mmol/L (HR 1.24, 95% CI 0.97–1.59 and HR 1.20,
95% CI 0.95–1.51, respectively). All-cause mortality was
also elevated in patients with hyperkalemia (4.7–5.0
mmol/L HR 2.36, 95% CI 1.68–3.30; 5.1–5.7 mmol/L HR
2.62, 95% CI 1.73–3.98). The univariable analysis showed
similar results. We observed no interaction between K1
and K2 on 60-day mortality.
Cardiovascular mortality accounted for nearly 53% of
all deaths. We observed increased risk of cardiovascular
death in patients with initial hypokalemia or low normal
potassium levels who had potassium concentrations <
3.0 mmol/L and > 4.6 mmol/L at the second
measurement.
The standardized 60-day absolute risk of all-cause
mortality was lowest in patients with potassium concen-
trations between 3.8–4.0 mmol/L (AR 5.4, 95% CI 4.5–
6.3%, Table 2). Significant differences in risks (reported
against the reference) were observed for the following
potassium intervals: 1.5–2.9 mmol/L risk difference 6.3%
(95% CI 2.9–9.7%); 4.7–5.0 mmol/L risk difference 6.2%
(95% CI 3.2–9.3%); 5.1–7.1 mmol/L risk difference 7.2%
(95% CI 2.8–11.6%).
Subgroup and sensitivity analyses
We performed eleven additional analyses to test the ac-
curacy and robustness of the main results (Table S6).
First, multivariable analysis performed on a subgroup
of patients without kidney insufficiency showed that po-
tassium levels within the intervals 1.5–2.9 mmol/L and
3.0–3.4 mmol/L were associated with increased mortality
risk compared with the reference (3.8–4.0 mmol/L) (HR
2.33, 95% CI 1.56–3.46 and HR 1.35, 95% CI 1.02–1.79,
respectively).
Second, in a subpopulation without history of malig-
nancy, adjusted analyses showed that potassium concen-
trations outside the interval 3.0–4.6 mmol/L were
associated with increased risk of death compared with
the reference.
Third, subgroup analysis on patients without history of
heart failure and no loop diuretic prescription showed
that patients with hypokalemia and hyperkalemia had an
increased mortality risk compared with patients with po-
tassium levels in the interval 3.8–4.0 mmol/L.
Fourth, analysis performed on a subgroup of patients
without ischemic heart disease showed that patients with
severe hypokalemia, and hyperkalemia had increased risk
short-term mortality risk when compared with the
reference.
Fifth, looking at patients with borderline hypokalemia
at the first potassium measurement, we observed that
patients who developed hypokalemia (1.5–2.9 mmol/L:
HR 2.16, 95% CI 1.25–3.73; 3.0–3.4 mmol/L: HR 1.70,
95% CI 1.22–2.37), or hyperkalemia (4.7–5.0 mmol/L:
HR 1.84, 95% CI 1.18–2.86; 5.1–7.1 mmol/L: HR 2.81,
95% CI 1.68–4.71) had an increased risk of death within
60-days when compared with the reference.
Sixth, among patients with hypokalemia at K1, analyses
showed that potassium concentrations within the inter-
vals 1.5–2.9 mmol/L, 4.1–4.6 mmol/L and 4.7–5.0 mmol/
L were associated with increased short-term mortality
risk.
Seventh, by performing the analyses on the last avail-
able potassium measurement within 6–100 days from K1
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instead of the first measurement, we noted that potas-
sium levels below 3.8 mmol/L were associated with in-
creased short-term mortality.
Eighth, analyses on patients with available K2 measure-
ments within 6–45 days from K1, showed that severe
hypokalemia and hyperkalemia were associated with 60-
day all-cause mortality.
Ninth, analyses on patients with available K2 measure-
ments above 45 days from K1, showed that potassium
interval 3.0–3.4 mmol/L was associated with 60-day all-
cause mortality.
Tenth, we stratified K2 in three intervals: 1.5–3.4
mmol/L (hypokalemia), 3.5–4.6 mmol/L (normokalemia)
and 4.7–7.1 mmol/L (hyperkalemia). Mortality within
60-days was increased both in patients with hypokalemia
(HR 1.36, 95% CI 1.12–1.66) and in patients with
hyperkalemia (HR 2.13, 95% CI 1.66–2.74) at K2 meas-
urement compared with patients with normal potassium
concentrations.
Eleventh, multivariable analysis on patients with avail-
able magnesium measurements at the time of plasma
potassium draws, showed significant association of po-
tassium levels below 3.0 mmol/L and mortality (HR 2.46,
95% CI 1.05–5.74). In addition, we also observed a trend
towards increased risk of death in patients with potas-
sium between 3.0–3.4 mmol/L.
Discussion
This Danish register-based cohort study investigated 60-
day mortality among 8976 patients with hypertension
and hypokalemia or low normal potassium in relation to
a subsequent potassium measurement. The major find-
ings were: (1) Persistent hypokalemia following low
potassium was more than twice as frequent as develop-
ment of hyperkalemia. (2) Persistent hypokalemia was
common and associated with increased all-cause and
presumed cardiovascular mortality; (3) Increase in potas-
sium to levels > 4.6 mmol/L in patients with initial hypo-
kalemia or low normal potassium was associated with
increased all-cause and cardiovascular mortality; (4)
Among patients with borderline hypokalemia initially,
development of hypokalemia or hyperkalemia was asso-
ciated with increased mortality risk; (5) Correcting hypo-
kalemia associated with increased survival.
In the current study, we observed significantly higher
60-day mortality risk in patients with potassium
Fig. 1 Age, sex, comorbidity and drug standardized 60-day risk of all-cause death in relation to plasma potassium as a continuous variable. Model
adjusted for age, gender, plasma sodium, renal insufficiency, malignancy, heart failure, chronic liver disease, chronic obstructive pulmonary
disease, diabetes mellitus, atrial flutter/fibrillation, stroke and ischemic heart disease, antihypertensive therapy, corticosteroids, antimicrobials, non-
steroidal anti-inflammatory drugs, potassium supplement, xanthines, laxatives
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concentrations < 3.5 or > 4.6 mmol/L after an episode
with hypokalemia or low normal potassium. This finding
was not surprising as we previously observed an appar-
ent optimal potassium range within 4.1–4.7 mmol/L in a
similar population [5]. Of 8976 patients with initial
plasma potassium ≤3.7 mmol/L, 18% had potassium con-
centrations ≤3.7 mmol/L at the second measurement
and 5.4% > 4.6 mmol/L, suggesting that potassium deficit
is frequently underestimated than overestimated by phy-
sicians. Notably, 13% of the patients with borderline
hypokalemia (K: 3.5 and 3.7 mmol/L) at the first
measurement experienced a further decrease in potas-
sium (< 3.5 mmol/L) at the second measurement. This
suggests that the association of low normal potassium
Fig. 2 All-cause and cardiovascular mortality after hypokalemia or borderline hypokalemia according to subsequent potassium measurements in
patients treated with combination antihypertensive therapy (60-days follow-up, n = 8976). Potassium interval K: 3.8–4.0 mmol/L represented the
reference range. Adjusted for age, gender, serum sodium, renal insufficiency, malignancy, heart failure, chronic liver disease, chronic obstructive
pulmonary disease, diabetes mellitus, atrial flutter/fibrillation, stroke and ischemic heart disease, antihypertensive therapy, corticosteroids,
antimicrobials, non-steroidal anti-inflammatory drugs, potassium supplement, xanthines, laxatives
Table 2 60-day standardized absolute risk for all-cause death after hypokalemia or borderline hypokalemia according to subsequent
potassium measurements in patients treated with combination antihypertensive therapy (n = 8976). Potassium interval K: 3.8–4.0
mmol/L represented the reference range. Adjusted for age, gender, serum sodium, renal insufficiency, malignancy, heart failure,
chronic liver disease, chronic obstructive pulmonary disease, diabetes mellitus, atrial flutter/fibrillation, stroke and ischemic heart
disease, antihypertensive therapy, corticosteroids, antimicrobials, non-steroidal anti-inflammatory drugs, potassium supplement,
xanthines, laxatives
Absolute risk %, (95% CI) 60-d Risk difference %, (95%CI) p-value Average risk ratio %, (95%CI) p-value
P(K) 1.5–2.9 mmol/L 11.7% (8.3–15.0) 6.3 (2.9–9.7) < 0.001 2.17 (1.46–2.88) 0.001
P(K) 3.0–3.4 mmol/L 7.1% (5.8–8.5) 1.7 (0.1–3.4) 0.03 1.32 (0.99–1.66) 0.06
P(K) 3.5–3.7 mmol/L 6.4% (5.3–7.5) 1.0 (− 0.3–2.4) 0.14 1.19 (0.91–1.47) 0.17
P(K) 3.8–4.0 mmol/L 5.4% (4.5–6.3) REF. REF.
P(K) 4.1–4.6 mmol/L 6.3% (5.4–7.2) 0.9 (−0.3–2.2) 0.13 1.18 (0.92–1.44) 0.17
P(K) 4.7–5.0 mmol/L 11.6% (8.7–14.6) 6.2 (3.2–9.3) < 0.001 2.17 (1.51–2.82) < 0.001
P(K) 5.1–7.1 mmol/L 12.6% (8.2–16.9) 7.2 (2.8–11.6) 0.001 2.34 (1.45–3.22) 0.003
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concentrations with mortality that we previously ob-
served [5] can partly be explained by further declines in
potassium levels, and that low normal potassium con-
centrations might be a marker for an ongoing decrease
in potassium.
Our results also suggest that correction of hypokal-
emia is important in relation to short-term mortality, as
patients in the middle of the normal reference interval
had good prognosis. Guidelines recommend supplemen-
tation with potassium when plasma potassium levels are
below 3.5 mmol/L. [13] However, in this study we can-
not elucidate because of the low follow-up time the
mechanism through which patients increased or de-
creased in potassium concentrations. It is also difficult
to state whether potassium is a risk factor or a risk
marker regarding mortality. Our population is relatively
old, patients are treated with at least two antihyperten-
sive drugs, and about 20% of the patients have history of
heart failure, ischemic heart disease, atrial fibrillation/
flutter, chronic obstructive pulmonary disease and dia-
betes. Possibly, potassium concentrations at non-
cardiotoxic levels more likely are a risk marker of great
disease burden, which is very important to recognize
and identify.
Potassium supplementation of asymptomatic patients
with low normal concentrations is controversial. Guide-
lines in the US recommend a stricter standard for potas-
sium replacement therapy (< 4.0 mmol/L) especially in
patients with cardiovascular disease who are at high risk
of ventricular tachyarrhythmias [13]. Our study suggests
that potassium concentrations in the middle of the refer-
ence interval are beneficial even in patients with potas-
sium levels ≤3.7 mmol/L.
Various studies have previously demonstrated that
hypokalemia among patients with cardiovascular disease
is associated with an increased mortality risk [14–18].
However, no prior studies have investigated the impact
of potassium normalization on short-term survival.
Though, one study examined the impact of correcting
hypokalemia within 24 h on the risk of cardiac arrhyth-
mias in hospitalized patients without coronary syn-
dromes or history of arrhythmias [19]. The authors did
not find increased odds of arrhythmia in patients with
hypokalemia whose potassium levels were not corrected
≥3.5 mmol/L. Although, the study does not describe or
account for the cause of admission, comorbidities or
pharmacotherapy. The investigators excluded patients
with history of ischemic heart disease and arrhythmia,
but included patients with heart failure who have a high
arrhythmia risk. Overall, both the study population and
the outcome measure differed in this paper compared
with our study.
Another study performed on 5916 individuals from
the general population found no significant associations
between borderline hypokalemia (3.4–3.6 mmol/L) and
risk of all-cause mortality, risk of stroke or risk of acute
myocardial infarction [20]. Comparing the results of our
study with this study is difficult due to major differences
in study population, methodology and aim. First, our
population was characterized by redemption of at least
two antihypertensive drugs. Mattsson et al. [20] enrolled
participants from the general population, where 49.6%
had high blood pressure at baseline, 13.9% were pre-
scribed heart medication and 10.9% were treated with
diuretics. In our population, we observed higher burden
of cardiovascular disease and use of diuretics. Second,
our aim was to investigate the impact of correcting
hypokalemia or borderline hypokalemia on short-term
all-cause and cardiovascular mortality. In terms of mor-
tality, Mattsson et al. [20] followed participants from
their fourth examination in 2001–2003 until November
2014 or death, having a median follow-up of 11.9 years
(Q1-Q3: 11.4–12.5 years). As potassium is varying over
time especially in patients with cardiovascular disease or
treated with antihypertensive drugs, use of one potas-
sium measurement to assess mortality over more than
10 years can provide results that are difficult to interpret.
Shorter follow-up time or time varying analysis where
the authors accounted for both multiple measurements
over time and change in relevant medication would have
provided better methodology. Although, it is important
to acknowledge that correcting hypokalemia and low
normal potassium might not have the same impact in
general population compared to a population with heart
disease.
Another study investigated the influence of dyskalemia
at admission and early dyskalemia correcting on short-
term survival and cardiac events among intensive care
unit (ICU) patients [21]. The authors concluded that pa-
tients with persisting hypokalemia or hyperkalemia
within the first 2 days in ICU had increased risk of
death. The two populations are not comparable, however
both studies emphasize the importance of rapid correc-
tion of hypokalemia to improve short-term mortality.
Limitations
The limitations are related to the observational nature of
register-based studies, which imply non-causal interpret-
ation of the results.
We did not have information about comorbidities and
risk factors from the primary sector. Therefore, patients
who did not redeem any medication of interest or were
not registered an ICD-code from the secondary sector
could have been misclassified as “healthy”. Patients with
complications related to hypertension have a larger like-
lihood for being referred to the secondary sector and
therefore also a higher probability for being diagnosed
with other conditions (compared with patients with
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uncomplicated hypertension), leading to an ascertain-
ment/surveillance bias and non-differential misclassifica-
tion bias. To reduce this bias, we defined hypertension
as use of at least two antihypertensive drugs in two con-
comitant quarters. Whether hypertension was resistant,
controlled or uncontrolled was unkown, and data about
ejection fraction and type of heart failure was not
available.
We cannot exclude that the blood draws may contain
hemolysis. However, in case of significant hemolysis the
samples submitted are rejected and no potassium value
is available.
We could not investigate the effect of any potential
treatment or drug dosage adjustment in the time be-
tween the first and second potassium measurement. The
Danish National Prescription Registry records filled pre-
scriptions; thus, changes in dosage cannot be identified,
unless a new drug is prescribed. In addition, the majority
of the patients were hospitalized at the time of
potassium measurement and any treatment during
hospitalization is not registered in the Danish National
Prescription Registry. Moreover, it was also difficult to
identify the cause of hypokalemia using the registers.
Hypokalemia might have occurred due to administra-
tion of diuretics, alkalosis, derangements in the renin
angiotensin aldosterone system, gastroenteritis or
other pathologies. However, the purpose of this study
was neither to investigate the cause of hypokalemia,
nor to assess the strategies used to correct low potas-
sium concentrations. The purpose of this study was
to find a clue, whether normalization of potassium
had an effect on short-term mortality, whether we
should increase potassium concentrations in patients
with borderline hypokalemia and whether potassium
actually increased.
It is also important to acknowledge that plasma potas-
sium is not always a good predictor of the whole body
potassium. Yet, it is the most commonly used method to
assess potassium and only in patients with persistent
hypokalemia over a longer period of time total body po-
tassium is calculated.
Conclusion
Persistent hypokalemia was frequent and associated with
increased all-cause and cardiovascular mortality. In-
crease in potassium to levels > 4.6 mmol/L in patients
with initial hypokalemia or low normal potassium was
associated with increased all-cause and cardiovascular
mortality.
Perspectives
We were not able to report the initiatives medical doc-
tors undertook after observing potassium levels below
3.8 mmol/L at the first measurement. However, our
results emphasize the importance of potassium
normalization after an episode with hypokalemia and
low normal potassium and that overcorrection is associ-
ated with an increased risk of death. Potassium concen-
trations in the middle of the normal reference interval
are associated with good prognosis. Possibly, potassium
supplementation, use of mineral receptor antagonists or
thiazide-like diuretics instead of thiazide-type in patients
with potassium concentrations ≤3.7 mmol/L could be of
clinical importance, but requires further study, prefera-
bly through a randomized controlled trial.
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Current guidelines for the management of hypertension rec-ommend 5 major drug classes, namely calcium channel 
blockers (CCB), ACE (angiotensin-converting enzyme) inhibi-
tors, ARBs (angiotensin receptor blockers), β-blockers, and 
thiazides/thiazide-like diuretics. In patients who do not have 
an optimal response on monotherapy, guidelines recommend 
sequentially adding other antihypertensive drugs until blood 
pressure target is achieved.1
Most of the drugs used for the treatment of hypertension, 
especially thiazide diuretics, ACE inhibitors, and ARBs, are 
known to influence potassium homeostasis through different 
mechanisms.2 In combination therapy, avoidance of potassium 
imbalances can be a challenge and prevention of potassium 
imbalances is important as they can elicit arrhythmias and 
sudden cardiac death.2–5 Moreover, a previous study showed 
that potassium levels outside the interval 4.1 to 4.7 mmol/L 
were associated with increased mortality risk in patients 
with hypertension.6 However, there is little knowledge on the 
occurrence of potassium imbalances in relation to different 
combination therapies.
Using the Danish nationwide administrative registries, 
we investigated the risk of developing hypokalemia within 
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Abstract—Little is known about the occurrence of hypokalemia due to combination therapy for hypertension. Using data 
from Danish administrative registries, we investigated the association between different combinations of antihypertensive 
therapy and risk of developing hypokalemia. Using incidence density matching, 2 patients without hypokalemia were 
matched to a patient with hypokalemia (K, <3.5 mmol/L) on age, sex, renal function, and time between index date 
and date of potassium measurement. Combination therapies were subdivided into 10 groups including β-blockers 
(BB)+thiazides (BB+thiazides), calcium channel blockers (CCB)+renin angiotensin system inhibitors (RASi)+thiazides 
(CCB+RASi+Thiazides), calcium channel blockers+thiazides (CCB+thiazides), and β-blockers+renin angiotensin system 
inhibitors+thiazides (BB+RASi+thiazides). We used conditional logistic regression to estimate the odds of developing 
hypokalemia for different combinations of antihypertensive drugs within 90 days of combination therapy initiation. We 
matched 463 patients with hypokalemia to 926 patients with normal potassium concentrations. The multivariable analysis 
showed 5.82× increased odds of developing hypokalemia if administered CCB+thiazides (95% CI, 3.06–11.08) compared 
with CCB+RASi. Other combinations significantly associated with increased hypokalemia odds were BB+thiazides (odds 
ratio, 3.34 [95% CI, 1.67–6.66]), CCB+RASi+thiazides (odds ratio, 3.07 [95% CI, 1.72–5.46]), and BB+RASi+thiazides 
(odds ratio, 2.78 [95% CI, 1.41–5.47]). Combinations of thiazides with CCB, RASi, or BB were strongly associated with 
increased hypokalemia risk within 90 days of treatment initiation.  (Hypertension. 2020;75:966-972. DOI: 10.1161/
HYPERTENSIONAHA.119.14223.) • Online Data Supplement
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Denmark: http://www.dst.dk/en/OmDS/organisation/TelefonbogOrg.
aspx?kontor=13&tlfbogsort=sektion or the Danish Data Protection 
Agency: https://www.datatilsynet.dk/english/the-danish-data-pro-
tection-agency/contact/. More information regarding data access is 
available at https://www.dst.dk/en/TilSalg/Forskningsservice.
Databases
All residents in Denmark have a personal, unique, and permanent 
civil registration number that enables linkage of data between all na-
tionwide administrative registries.
We used The Danish Civil Registration System7 to collect data re-
garding age and gender. From The Danish National Patient Registry,8 
we obtained information about hospital admission dates, hospital dis-
charge dates, discharge diagnoses, dates of operation, and procedure 
codes. Diagnoses are classified as primary and secondary according 
to World Health Organization International Classification of Disease. 
From 1994 and onwards the International Classification of Disease, 
Tenth Revision was in use. The Danish National Patient Registry cov-
ers information from 1978 until present time.
From The Danish National Prescription Registry,9 information 
on each individual’s drug redemption was collected. This regis-
ter includes all dispensed prescriptions from all Danish pharmacies 
since 1995 based on the Anatomic Therapeutic Chemical system. 
The Danish healthcare system is state-financed and partly reimburses 
drug costs. For this reason, all Danish pharmacies are required by law 
to register all dispensed drug prescriptions, providing a complete o-
verview of all prescriptions. From 1995, registries of laboratory data 
contain blood test results from 3 of the 5 regions in Denmark, cover-
ing ≈ 4 058 000 inhabitants.
Study Population and Design
Hypertension was defined as the redemption of at least 2 antihyper-
tensive drugs in 2 consecutive quarters. Patients entered the study 
after the first occurrence of redeeming prescriptions for combina-
tion antihypertensive therapy in 2 subsequent quarters.10 This time 
was referred to as the index date. Anatomic Therapeutic Chemical 
codes of the drugs used to define patients as having hypertension 
were included in Table S1 in the online-only Data Supplement. We 
defined hypertension as redemption of at least 2 antihypertensive 
drugs in at least 2 consecutive quarters for different reasons. First, 
by using Danish registries, it was difficult to ascertain whether 
patients were treated for hypertension with monotherapy only. The 
majority of the drugs used to treat high blood pressure can be used 
for other cardiovascular diseases, such as atrial fibrillation, heart 
failure, or myocardial infarction. Second, by using diagnosis code 
approach to identify patients with hypertension, we would have 
lost a considerable sample of patients as in many cases treatment 
and monitoring takes place in a primary care setting. In a study by 
Olesen et al,10 this definition of hypertension was validated and 
the authors found that the positive predictive value of treatment 
with 2 classes of antihypertensive drugs was 80% and the speci-
ficity 94.7%.
The first potassium measurement within 90 days from index date 
was kept methods for blood potassium analysis have not been simi-
lar in all laboratories over the entire study period, having measured 
both serum and plasma potassium concentrations. As the normal 
ranges for the 2 methods of measuring blood potassium concentra-
tions do not differ substantially, we referred to all measurements as 
serum potassium.
Exclusion criterias were age below 18 years, no potassium meas-
urement up to 30 days before index date, hypokalemia, or hyper-
kalemia up to 30 days before index date, hyperkalemia at the first 
potassium measurement after combination therapy initiation and pre-
scription of loop diuretics. The population flow chart with inclusion 
and exclusion criteria was shown in Figure S1.
This study used a nested case-control design. Using incidence 
density matching, 2 patients without hypokalemia (K, >3.5 mmol/L; 
n=926) were matched to each patient with hypokalemia (K, <3.5 
mmol/L; n=463) on age, sex, renal function, and time between index 
date and date of potassium measurement.
Comorbidities, Procedures, and Concomitant 
Medication
The following discharge diagnoses present before index date were 
assessed to characterize the population: heart failure, ischemic heart 
disease, acute myocardial infarction, atrial fibrillation, atrial flutter, 
second- or third-degree atrioventricular block, ventricular tachy-
cardia or fibrillation, stroke, chronic obstructive pulmonary disease, 
chronic liver disease, inflammatory bowel disease, diabetes mellitus, 
hypothyroidism, cancer, and stroke. None of the patients had a his-
tory of diabetes insipidus, syndrome of inappropriate antidiuretic 
hormone secretion, primary hyperaldosteronism, or Addison disease.
The kidney function of each patient was assessed by calculating 
the estimated glomerular filtration rate (eGFR),11 and an eGFR <30 
mL/(min·1.73 m2) suggested renal insufficiency. This cutoff level 
was chosen, as we did not have information on whether patients had 
evidence of kidney damage (ie, albuminuria, hematuria, structural 
changes, or biopsy verification). Serum creatinine used to calculate 
eGFR was obtained within 7 days before potassium measurement, 
and patients with missing creatinine values were excluded.
From the Danish National Prescription Registry, we identified 
the following redeemed medication known to be associated with 
potassium disturbances: potassium supplements, antimicrobials, 
β2-agonists, mineralo- and glucocorticoids, laxatives, xanthines, 
and macrolides. Only potassium supplementation, antimicrobials, 
and β2-agonists were present in the nested case-control population. 
Potassium supplements were supplements as a single pill therapy 
combined with an antihypertensive (Anatomic Therapeutic Chemical 
C03) or as an individual pill (ATC A12B). Definitions of comorbidi-
ties and concomitant medication before index date were illustrated 
in Table S2.
Statistical Analyses
Categorical variables were reported as counts and percentages and 
continuous variables as medians with 25th to 75th percentiles. 
Differences between variables were compared using χ2 and Kruskal-
Wallis tests, as appropriate.
An incident episode of hypokalemia was defined as a blood potas-
sium level <3.5 mmol/L within 90 days from index date.
Cumulative incidence proportion curves for developing hypoka-
lemia in patients treated with combination antihypertensive therapy, 
who had available potassium measurements within 90 days from in-
dex date and no potassium imbalances up to 30 days before index 
date, were estimated.
The independent variable defining the different possible combina-
tions of antihypertensive treatment was coded as a dummy variable 
with the 10 most frequent possibilities identified in the population:
1. BB (β-blockers)+CCB
2. BB+RASi (renin-angiotensin system inhibitors)








Antihypertensive drug groups 1, 6, 7, and 8 referred to combinations 
of CCBs with other blood pressure drugs. However, these groups only 
contain one type of CCBs, namely dihydropyridine derivatives, such 
as amlodipine. Conditional logistic regression analysis was used to 
estimate the odds ratio and 95% CI between different combination 
therapies and developing hypokalemia with CCB+RASi as reference.
When investigating the association between hypokalemia and the 
10 antihypertensive drug groups the model was adjusted for initial se-
rum sodium, malignancy, inflammatory bowel disease, diabetes mel-
litus, and chronic liver disease.
As some of the antihypertensive drug combinations can also indi-
cate cardiovascular diagnoses other than hypertension, we performed 
a sensitivity analysis where we also matched the controls on history 
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A 2-Sided P Value <0.05 was considered statistically significant 
since not every patient with hypertension, treated with combination 
therapy, had a potassium measurement available within 90 days from 
treatment initiation, we also looked at the prevalence of different co-
morbidities between our population and the general population with 
no potassium concentrations within the predefined timeline.
Data management and analyses were performed using SAS, ver-
sion 9.4 (SAS Institute, Inc, Cary, NC) and R, version 3.5.1 (R Core 
Team [2018]). R: A language and environment for statistical comput-
ing. R Foundation for Statistical Computing, Vienna, Austria; https://
www.R-project.org/.
Ethics
The Danish Data Protection Agency approved the use of data (ref-
erence: 2007-58-0015, internal reference: GEH-2014-015, I-Suite 




Population characteristics of the cohort, from which cases and 
controls were identified and matched on different variables, 
were illustrated in Table S3. During 1995 to 2018, 11 896 
patients treated for hypertension with combination therapies 
had a potassium measurement within 90 days of index date. 
Among the patients, 3.9% had potassium concentrations 
below 3.5 mmol/L. Furthermore, we observed that 48.5% of 
the patients redeemed thiazides, of which 1.6% were thiazide-
like diuretics and 45% hydrochlorothiazides. Additionally, 
31.8% of the population was prescribed potassium supple-
ments, of which 86.7% represented potassium chloride as 
single pill combined with an antihypertensive.
After matching on age, sex, eGFR, renal insufficiency, 
and time from index date to potassium measurement, we 
ended up with 463 cases and 926 controls. Median time 
from index date to potassium measurement was 30 days 
(0, 90). Following proportions were observed in each of 
the 10 combination antihypertensive therapies: BB+CCB 
4.3%, BB+RASi 16.9%, BB+RASi+mineral receptor an-
tagonist 3.2%, BB+RASi+thiazides 4.0%, BB+thiazides 
4.4%, CCB+RASi 12.5%, CCB+RASi+thiazides 6.5%, 
CCB+thiazides 6.7%, RASi+thiazides 12.2%, and Other 
combinations 12.2% (Table).
We also observed higher prevalence of hypoka-
lemia in patients redeeming CCB+thiazides (12.1%) and 
RASi+thiazides (30.7%) than in patients treated with any of 
the other drug groups. Among the cases (with hypokalemia), 
45.8% redeemed potassium supplement.
Antihypertensive Combination Therapies and Risk 
of Hypokalemia
Figure S2 illustrated the cumulative incidence proportion of 
hypokalemia in patients treated with combination antihyper-
tensive therapy who had available potassium measurements 
within 90 days of the index date and no potassium imbalances 
up to 30 days before index date (n=11 896). After stratifying 
on the 10 combination therapies the cumulative incidence 
curves showed that the combination of CCB+thiazides had a 
significantly higher incidence of hypokalemia than the other 
groups (about 10%; Figure S3).
In the nested case-control population the adjusted con-
ditional logistic regression analysis with CCB+RASi as 
reference showed 5.82× increased odds for development 
of hypokalemia if administered CCB+thiazides (95% CI, 
3.06–11.08). Moreover, patients on BB+thiazides had an odds 
ratio of 3.34 for developing hypokalemia (95% CI, 1.67–
6.66). Other drug combinations significantly associated with 
increased hypokalemia risk were CCB+RASi+thiazides (odds 
ratio, 3.07 [95% CI, 1.72–5.46]) and BB+RASi+thiazides 
(odds ratio, 2.78 [95% CI, 1.41–5.47]; Figure). The univari-
able analysis showed similar results (Figure S4).
Sensitivity Analyses
We performed an additional conditional logistic regression 
analysis on a population matched on age, sex, eGFR, renal in-
sufficiency, time from index date to potassium measurement, 
heart failure, and ischemic heart disease/myocardial infarc-
tion. The results were similar to the main analyses, though 
with slightly lower effect sizes (Figure S5 and Figure S6).
We also looked at differences in comorbidity proportions 
in our nested case-control population versus general popula-
tion treated with combination antihypertensive therapy who 
did not have available serum potassium measurements within 
90 days from index date. We observed that nearly all comor-
bidities had higher rates in the nested case-control population 
than in the general population. See Table S4 and the Table for 
general population demographics.
Discussion
The main findings in this article were (1) hypokalemia among 
patients treated with combination antihypertensive thera-
pies was common, (2) the 3 antihypertensive drug combina-
tions with the highest odds of developing hypokalemia were 
CCB+thiazides, BB+thiazides, CCB+RASi+thiazides.
Current guidelines recommend combination antihyperten-
sive drug treatment strategies in patients not achieving targeted 
blood pressure.1 Pharmacologically, the great majority of the 
patients in this study were treated with combination therapies 
with opposite effects on potassium homeostasis. Despite this 
approach, the occurrence of hypokalemia remained high con-
sidering the short study period. A large scale Swedish study 
investigating determinants of hyperkalemia and hypokalemia 
showed that patients with hypertension had 1.80 and 1.05× 
higher odds of developing hypokalemia and hyperkalemia 
within 3 years, respectively.12 This is in line with our find-
ings where we observed increased odds of hypokalemia re-
lated to some specific antihypertensive combination therapies. 
Yet, the 2 studies are not utterly comparable as we both had 
different approaches for defining hypertension (International 
Classification of Disease codes versus 2 concomitant antihy-
pertensive drugs) and different aims.
Comparison of our findings with other studies was difficult, 
as the great majority of previous articles focused on outcomes 
like stroke and cardiovascular events1 instead of dyskalemias. 
We found that CCB+thiazides, CCB+RASi+thiazides, and 
BB+thiazides were highly associated with increased risk of 
hypokalemia when compared with CCB+RASi. In the follow-
ing paragraphs, each of the drug combinations and their asso-
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CCB+Thiazides
A meta-analysis based on the results of 4 randomized trials 
investigated the efficacy and safety of CCBs and thiazide 
(-like) diuretics. The authors observed that the most frequent 
adverse event related to CCB+diuretic combination was 
hypokalemia.13 Because of the insufficient knowledge about 
dyskalemias caused by CCB+thiazides, we searched liter-
ature treating the 2 drugs individually. There is little recent 
knowledge on the effect of CCB on potassium homeostasis 
either in large or small-scale studies. On one hand, numerous 
Table. Demographics of the Matched Population
Controls (n=926) Cases (n=463) Total (n=1389) P Value
Sex
  Female 484 (52.3)* 242 (52.3)* 726 (52.3)* 1.0*
Age, median (range) 65.0 (21.0–95.0)* 66.0 (23.0–95.0)* 65.0 (21.0–95.0)* 0.55*
Days from hypertension to potassium 
measurement, median (range)
30.0 (0.0–90.0)* 31.0 (0.0–90.0)* 30.0 (0.0–90.0)* 0.68*
Serum sodium, median (range) 140.0 (113.0–146.0)* 140.0 (118.0–148.0)* 140.0 (113.0–148.0)* 0.15*
Renal insufficiency 10 (1.1)* 5 (1.1)* 15 (1.1)* 1.0*
eGFR, median (range) 77.0 (10.0–214.0) 79.0 (7.0–222.0) 78.0 (7.0–222.0) 0.32
Treatment combinations
  BB+CCB 41 (4.4) 19 (4.1) 60 (4.3)  
  BB+RASi 195 (21.1) 40 (8.6) 235 (16.9)  
  BB+RASi+MRA 40 (4.3) 4 (0.9) 44 (3.2)  
  BB+RASi+thiazides 33 (3.6) 23 (5.0) 56 (4.0)  
  BB+thiazides 32 (3.5) 29 (6.3) 61 (4.4)  
  CCB+RASi 134 (14.5) 40 (8.6) 174 (12.5)  
  CCB+RASi+thiazides 49 (5.3) 42 (9.1) 91 (6.6)  
  CCB+thiazides 37 (4.0) 56 (12.1) 93 (6.7)  
  RASi+thiazides 264 (28.5) 142 (30.7) 406 (29.2)  
  Other combinations 101 (10.9) 68 (14.7) 169 (12.2) < 0.0001
Heart failure 153 (16.5) 30 (6.5) 183 (13.2) < 0.0001
IHD/MI 224 (24.2) 68 (14.7) 292 (21.0) < 0.0001
COPD 56 (6.0) 30 (6.5) 86 (6.2) 0.84
Diabetes mellitus 121 (13.1) 41 (8.9) 162 (11.7) 0.03
Chronic liver disease 24 (2.6) 9 (1.9) 33 (2.4) 0.57
Hemodialysis ≤3 ≤3 ≤6 …
Malignancy 115 (12.4) 73 (15.8) 188 (13.5) 0.10
Stroke 83 (9.0) 55 (11.9) 138 (9.9) 0.11
Atrial flutter/fibrillation 120 (13.0) 41 (8.9) 161 (11.6) 0.03
Atrioventricular block 13 (1.4) ≤3 ≤16 …
VT/VF 36 (3.9) 13 (2.8) 49 (3.5) 0.38
Inflammatory bowel disease 16 (1.7) 11 (2.4) 27 (1.9) 0.54
Hypothyroidism 18 (1.9) 9 (1.9) 27 (1.9) 1.0
Potassium supplement 312 (33.7) 212 (45.8) 524 (37.7) < 0.0001
Antimicrobials ≤3 ≤3 ≤6 …
β-2 agonists ≤3 ≤3 ≤6 …
Potassium supplement addressed supplementation as a single pill therapy with an antihypertensive and as an individual pill. We attribute 
<=3 to variables with values between 1 and 3 to secure anonymity and protection of personal data. BB indicates β-blockers; CCB, calcium 
channel blockers; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter-
defibrillator; IHD/MI, ischemic heart disease/myocardial infarction; MRA, mineral receptor antagonist; RASi, renin-angiotensin system 
inhibitors; and VT/VF, ventricular tachycardia/ventricular fibrillation.
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in vitro, in vivo and case report publications reported hyper-
kalemia following initiation of CCB.14–19 On the contrary, case 
studies and studies on rats showed hypokalemia in relation 
to administration of CCB.20–25 As for thiazide diuretics, nu-
merous studies showed that monotherapy is associated with 
development of hypokalemia.26–28 The mechanisms through 
which the 2 drug types lead to hypokalemia seemed to be very 
different: thiazides enhance renal potassium disposal, while 
CCBs augment extrarenal loss of potassium.21,29–31 However, 
the mechanisms through which CCB can cause both hypo- 
and hyperkalemia are poorly elucidated.
CCB+RASi+Thiazides
No study directly compared the risk of hypokalemia related 
to this combination therapy in relation to other combination 
therapies. Most studies compare the risk of hypokalemia in 
patients treated with thiazides alone versus different combina-
tions of antihypertensive drugs with complementary effect on 
potassium homeostasis.32
BB+Thiazides
The combination of BB and thiazides is no longer first-line 
treatment of arterial hypertension but certainly an effective 
combination in prevention of adverse cardiovascular events.1 
To our knowledge, no study reported increased hypokalemia 
risk in patients prescribed BB+thiazides. Although we do 
know that use of thiazides diuretics can lead to hypokalemia,33 
while use of some BB is associated with increased hyperka-
lemia risk especially in patients with renal dysfunction and 
insulin insufficiency.33
Our results suggested that high odds of hypokalemia 
were strongly related to the use of thiazides as they were pre-
sent in each of the combination therapy groups with signif-
icant increased odds of low potassium concentrations. This 
adverse effect was also observed in patients administered po-
tassium supplements.
Should we be concerned about hypokalemia? Both hypo-
kalemia and hyperkalemia have previously been shown to be 
associated with increased risk of all-cause mortality6,34,35 and 
cardiovascular disease36 in different populations with heart di-
sease. Regarding patients with hypertension, current studies 
have discrepant results. In a previous study, we found that po-
tassium concentrations outside the interval 4.1 to 4.7 mmol/L 
were associated with increased mortality risk.6 Contrarily, 
Franse et al37 found no significant difference in the relative risk 
of all-cause mortality for participants who received low-dose 
chlorthalidone and who experienced hypokalemia compared 
with placebo group. Additionally, Alderman et al38 observed a 
higher all-cause mortality (hazard ratio, 1.21) in patients with 
hypokalemia than in normokalemics. However, the authors 
also found heterogeneity in hazard ratios across the 3 treatment 
arms (chlorthalidone, amlodipine, and lisinopril). Comparison 
of the 3 studies is difficult as the only common features were 
that patients were treated for hypertension and had their blood 
potassium measured. Yet, there are 2 very essential differences 
in these studies that could explain the discrepancy in results, 
namely the burden of disease. First, in our large epidemiolog-
ical study, we included patients who redeemed at least 2 con-
comitant antihypertensive drugs,6 while the randomized trials 
either compare monotherapy with placebo or monotherpies 
within themselves. Undoubtely, patients included in the epi-
demiological study had more advanced hypertension that the 
patients in the randomized trials.
Second, the time when mortality was assessed could be 
a strong influencer of the results. The randomized trials used 
year-1 potassium measurement to investigate long-term mor-
tality (y), while we examined the effect of different potassium 
concentrations measured within 90 days from combination 
antihypertensive therapy on 90 days all-cause mortality.6,37,38 
Ultimately, we believe that hypokalemia is an important risk 
factor or risk marker of cardiovascular disease and mortality. 
Yet, further studies are needed to explain which patients are at 
high risk of adverse effects after an episode of hypokalemia.
Limitations
Most of the limitation were related to the observational nature 
of the study design meaning that unmeasured confounding 
such as vomiting, diarrhea, and diet may affect our findings. 
Information on the clinical indication for blood tests or symp-
toms of dyskalemias and electrocardiographic changes were 
not available. However, according to guidelines patients with 
hypertension need to have their blood pressure monitored 
and standard blood test performed within 3 to 6 months of 
treatment initiation. Therefore, we believe that cases where 
clinicians specifically test for potassium imbalances in our 
population are negligible.
Furthermore, due to the short follow-up time, it was diffi-
cult to calculate dosage of redeemed antihypertensive drugs. 
Figure. Forestplot of multivariable conditional 
logistic regression analysis for the development 
of hypokalemia. Population matched on age, 
sex, renal insufficiency, and time index date 
initiation to serum potassium measurement. 
The model was adjusted for serum sodium, 
renal insufficiency, malignancy,  inflammatory 
bowel disease, diabetes mellitus, alcoholism, 
and chronic liver disease. The combination 
of calcium channel blockers with renin-
angiotensin system inhibitors was used as 
reference. BB indicates β-blockers; CCB, 
calcium channel blockers; MRA, mineral 
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Therefore, compliance issues or overdose could not be identi-
fied for any of the drug groups, which can lead to nondifferen-
tial misclassification.
Finally, the fact that potassium concentrations were meas-
ured in both serum and plasma within the different laborato-
ries over the years is an inevitable limitation, due to cases with 
misclassification of the patients. Reference ranges for normal 
serum potassium and plasma potassium concentrations do not 
differ substantially. The Nordic Reference Interval Project 
recommends that an interval of 3.6 to 4.6 mmol/L is consid-
ered to be normal for serum potassium, whereas an interval 
of 3.5 to 4.4 mmol/L is suggested to be normal for plasma 
potassium.39 False-positive hyperkalemia was presumably 
uncommon as all laboratories left out reporting of potassium 
values in presence of hemolysis.
Conclusions
Combinations of thiazide diuretics with CCB, RASi, or BB 
were strongly associated with increased hypokalemia risk 
within 90 days of treatment initiation, regardless of potassium 
supplementation.
Perspectives
Focus on optimal management of hypertension in clinical 
practice is emphasized in the current practice due to the 
numerous studies showing benefits both related to the risk 
of death but also to cardiovascular comorbidity and health-
related quality of life.40,41 Hypo- and hyperkalemia are com-
mon side effects of the drugs used to treat hypertension. 
Awareness of the risk factors associated with potassium 
disturbances is important to identify patients at risk. For 
example, our study strongly suggested that patients treated 
with CCB+thiazides had an increased probability of devel-
oping hypokalemia within 90 days from index date, despite 
potassium supplementation. Therefore, it would be prudent 
to recommend identifying and closely monitoring patients 
at high risk of potassium imbalances as important goals in 
everyday clinical settings.
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What Is New?
•	Patients treated with thiazide diuretics in combination with calcium 
antagonists, β-blockers, or renin-angiotensin system inhibitors had an 
increased hypokalemia risk within 90 days from combination therapy 
initiation.
•	 Increased hypokalemia risk was observed also in patients administered 
potassium supplements.
What Is Relevant?
•	 Increased hypokalemia risk was present despite all patients being treat-
ed with combination of antihypertensive drugs with opposite effect on 
potassium homeostasis and despite supplementation with potassium in 
some of the cases.
•	 Low potassium concentrations have previously been associated with 
arrhythmogenesis and increased mortality risk in patients with hyper-
tension.
Summary
In this register study comprising 463 patients with hypokalemia 
and 926 patients with normal potassium concentrations, we ob-
served that combination of thiazides with β-blockers, calcium 
channel blockers, and renin-angiotensin system inhibitors had 
increased hypokalemia risk compared with the combination of cal-
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